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2.4 Quantitative analysis of the distribution of TMR-PSINPs in both com-
pressed and intact spinal cord segments-1. The fluorescence probe sig-
nals of intact cords in white matter were normalized against the signals
recorded from compressed cords. Data was expressed as a percent of the
intensity at site 0. Site enumeration as above. Compared with site 0,
the intensity was statistically significantly reduced at site 1(P<0.05) and
site 3 (P<0.01). At site 2, a reduction of the intensity of the signal was
observed as well, but the significance of the difference was not reached.
(n=3). Data was expressed as mean±SD. . . . . . . . . . . . . . . . . 28
2.5 Quantitative analysis of the distribution of TMR-PSINPs in both com-
pressed and intact spinal cord segments-2. Injured (Site 0) is the site of
compression as above. Site enumeration as above. Compared with injured
(site 0), the intensity of TMR-PSINPs was reduced at site 1, site2, and
site3 significantly (P<0.01). Results are expressed as a percent of the
uninjured values ±SD (n=5). **P<0.01, ***P<0.001. . . . . . . . . . 29
2.6 Qualitative evaluation of PSINPs in both compressed and intact spinal
cord segments by SEM. Spinal cord segments incubated with PSINPs
were examined at the compression injury, site 0(a) and the proximal in-
tact sites 1(b), site 2(c), and site 3(d). The dense accumulation of PSINPs
was observed in (a), the compressed spinal cord sample, whereas uptake
of PSINPs was minimized in site 1(b), site 2(c), and site 3(d), the in-
tact spinal cord segments. Individual and aggregated NPs were partially
indicated with green and yellow color in post-analysis. . . . . . . . . . 30
3.1 The chemical compositions of gluocosamine and aceytl-glucosamine. The
monomer is defined as glucosamine if R position is occupied by a proton.
The monomer is defined as acetyl-glucosamine if R position is occupied as
an acetyl group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.2 The chemical compositions of chitin and chitosan. Chitin is defined when
R1 and R2 positions are occupied by acetyl groups. Chitosan is defined if
a part of positions (R1 and R2) is occupied by protons. The percent can
be varied from 0%-100%. n and m represent the number of monomers in
the polymer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.3 The illustration of a phospholipid molecule on the cell membrane. A phos-
pholipid molecule is composed of the hydrophilic head (an organic group,
a phosphate group, and a glycerol backbone) and the hydrophobic tail
(fatty acids). The organic groups of a phospholipid can be choline, ser-
ine, ethanolamine, and inositol. The cell membrane is charged negatively
overall which is contributed mainly by the anionic phosphate groups. . 40
xii
Figure Page
3.4 The illustration of the conjugation of FITC-chitosan. A thiourea bond is
formed between the isothiocyanate reactive group (-N=C=S) of a FITC
molecule and the amino-group of chitosan polymer. . . . . . . . . . . . 45
3.5 The fluorescence intensity of TMR uptake after transection injury and
its inhibition by different chitosan treatments. (A) Fluorescence inten-
sity of TMR uptake in a cross-section of spinal cord given transection
injury with PBS treatment (control). (B-H) Cross-section graphs showing
different degrees of decreasing fluorescence intensity of TMR labeling in
transected spinal cord with chitosan treatments. (B) Transection injury
with DA100 treatment. (C) Transection injury with DA20 treatment.(D)
Transection injury with DA10 treatment.(E) Transection injury with DA0
treatment.(F) Transection injury with Low MW treatment. (G) Tran-
section injury with Medium MW treatment.(H) Transection injury with
Oligo MW treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.6 Quantification of normalized fluorescence intensity of TMR uptake as a
function of chitosan treatments. The fluorescence intensity in PBS group
used as the control. Note that all chitosan treatments significantly de-
creased the fluorescence intensity of TMR uptake following the transection
injury, *P<0.05 , ** P<0.01 (Dunnett test). N=6. . . . . . . . . . . . . 48
3.7 Quantification of normalized fluorescence intensity of LDH leakage as a
function of chitosan treatments. The fluorescence intensity in PBS group
was used as the control. Note that all chitosan treatments significantly
decreased the fluorescence intensity of LDH leakage following the compres-
sion injury, *P<0.05 (Dunnett test). N=6. . . . . . . . . . . . . . . . . 49
3.8 The distribution of FITC-Chitosan on injured (compression injury) and
intact spinal cord segments. No obvious difference of the labeling of FITC-
Chitosan was observed between the injured and intact cords. (A). The
cord with the compression injury. (B). The cord without the compression
injury. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
xiii
Figure Page
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ABSTRACT
Chen, Bojun Ph.D., Purdue University, December 2013. Neuroprotection by Chitosan
and Chitosan Nanoparticles. Major Professor: Richard B. Borgens.
In the U.S., about 200,000 people are currently living with spinal cord injury
(SCI). An estimated of 50%-70% of all SCI cases occurs in the range of ages between
15-35 years old. The destructive neurotrauma results in the majority of adult dis-
ability, even after patients suffering with SCI survived from the acute death. There
are two stages involved in the progression of SCI, the primary stage and the sec-
ondary stage. The primary stage is mainly the mechanical damage to the central
nervous system. The rapid collapse of the integrity of cell membrane and tissue is
often one of the initial onsets. Centered by the cascade of biochemical disruption,
such as aldehyde toxins, the secondary injury is responsible for the major clinical
deficits in sensory and motor functions. Available pharmacological treatment for
SCI includes high doses of steroids. However, the side effects of steroid therapy
leave patients more susceptible for complications, such as infections, chronic pain
and blood clots. The absence of “standard of care” have triggered waves of intense
research leading to “finding a cure for SCI”. Based on our previous successful ex-
plorations of the neuroprotection by chitosan and chitosan nanoparticles (Chi-NPs)
in SCI related cell and tissue studies, we further investigated the neuroprotective
effects based on two major characteristics of chitosan: (1) molecular weight (MW)
and (2) degree of acetylation (DA). Our results demonstrated that chitosan polymer
blocked the random exchange of a probe, tetramethyl-rodamine (TMR) and an en-
dogenous protein, lactate dehydrogenase (LDH), across mechanically compromised
cell membrane, while a significant difference of the membrane “sealing” effect was
not suggested among different MWs and DAs of chitosan polymer. A similar affinity
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of FITC-chitosan polymer at intact and injured spinal tissues was also suggested. To
push the use of chitosan a step towards clinical tests, we incorporated the advan-
tage of nanomedicine with our “promising chitosan material”. Different factors were
investigated during the formation and the storage of Chi-NPs. Two types of Chi-
NPs (chitosan-triphosphate, Chi-TPPNPs and chitosan-dextran sulfate, Chi-DSNPs)
were synthesized, with a range of size at 100-300nm and zeta-potentials of 30.65mV
and -47.4mV, based on an ionic gelation method. Chi-DSNPs were shown to rescue
necrotic BV-2 cells induced by a short incubation of hydrogen peroxide at 5.5mM.
In addition, the conduction of somatosensory evoked potentials (SSEPs) through the
lesion produced by the compression injury was partially restored after 1 week of the
subcutaneous administration of Chi-DSNPs. We also found that polyethylene glycol
(PEG)-coated silica NPs were significantly accumulated at the compression injured
spinal tissues. The affinity of NPs at severed cell membranes was guided by PEG. Our
experimental findings suggested that chitosan and ChiNPs provided neuroprotective
effects using both in vitro and in vivo models.
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1. INTRODUCTION
The central nervous system (CNS), as part of the nervous system, consists of the
brain and spinal cord. The CNS serves as the command center that gives order
and receives feedback from organs and limbs through neural pathways of peripheral
nervous system (PNS). Extending from the brain, the spinal cord transmits motor
(descending) and sensory (ascending) signals between the brain and the rest of the
body. If the brain is considered as a hub for generating human motor, intellectual
and emotional information, then, the spinal cord is the interconnecting network that
coordinates nerve reflexes and transmits these motor and sensory signals in the body.
In a sense, it is the spinal cord that acts as the informational highway that enables
human behavior [1].
Spinal cord injury (SCI) occurs most commonly via compression, resulting from
spinal fracture or dislocation by direct mechanical forces on the vertebral column.
Based on the injury level at the vertebral columns, SCI can result in neurologic func-
tion deficits below the lesion, while normal functions are still preserved above the site
of insult. In severe injury cases, SCI can lead to paralysis and even death. A succes-
sion of complications can follow SCI, such as neurologic deterioration, pressure sores,
aspiration and pulmonary problems. Both SCI and its complications create tremen-
dous financial burden on individuals and the society. The average annual medical cost
for treating SCI is $15,000-$30,000. Among others, falls, violence and sports, motor
vehicle accidents (46%) are the leading causes of SCI. The most frequently occurring
age at injury is 19. The average estimated lifetime cost is more than $3 million and
injured persons can live close to a normal life span [2]. All these facts make SCI the
most expensive and untreatable traumatic injury to the human body.
The history of SCI management can be traced to World War II, when people died
from secondary complications [1]. The widespread development and use of antibiotics
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changed these outcomes, but did not lead to functional returns. Unfortunately, com-
pared with the breakthroughs and remarkable movements in burn control, fracture
nonunions, and even cancer, there is still no way to reverse the damage in SCI. This
is mainly derived from the complexity and multi-factorial nature of SCI. The only
current therapy option is steroid therapy (Methylprednisolone, MP). The adminis-
tration of MP in the acute phase of SCI was claimed to be useful in SCI by reducing
the free radical mediated damage in the national acute spinal cord injury studies
(The National Acute Spinal Cord Injury Studies, NASCIS) II and III clinical trials.
However, this steroid therapy was not recommended by the Congress of Neurological
Surgeons / the American Association of Neurological Surgeons (AANS) spelled out
in 2013, due to the lack of placebo-controlled trial design and harmful side effects
of infection and avascular necrosis [3, 4]. Moreover even earlier critics pointed out
the exaggerated claims and dubious statistical comparisons used by NASCIS inves-
tigators [1]. The therapy thus was never taken as proven beneficial nor considered
as any form of “standard of care”. Other neuroprotective interventions have shown
either no clear benefit for SCI or raised the concern of medical side effects: such as
GM-1 ganglioside, the NMDA antagonist gacyclidine, Neotrofin, Prochord injection
therapy, to name only a few [1, 5–7]. The lack of standard pharmacological protocol
for SCI management and repair justified and triggered extensive investigations to new
treatments.
This introduction will: 1) review the anatomy of spinal cord and pathophysiology
of SCI; 2) emphasize the role of the distortion of the membrane integrity as an ini-
tiator in primary injury and as a critical turning point in SCI from primary injury
to proceeding secondary injury; 3) summarize the advantages and disadvantages of
different neuroprotective strategies and 4) discuss the opportunities for nanomedicine
applications.
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1.1 The anatomy of spinal cord
The human spinal cord is located in the vertebral column. It extends from the
medulla oblongata which is a lower part of the brain stem, through the foramen
magnum (one of the large openings in the base of the skull) and ends with the conus
medullaris. Spinal cord is divided into 8 cervical (C), 12 thoracic (T), 5 lumbar (L),
5 sacral (S), and 3 coccygeal segments. At each segment, one pair of nerve (dorsal
and ventral) roots which are located on the left or right side of the vertebral column
extends away from spinal cord tissue, bundled together as one spinal nerve, and
innervates end targets, organs and muscles to transmit mortor and sensory signals in
an orderly manner. The level of spinal cord is named after the origins of the spinal
nerves. The spinal cord is enveloped by three layers of membranes, also called as
spinal meninges. From the outermost to the innermost, there are the dura matter,
the arachnoid matter, and the pia matter.
At the central area of the spinal cord, it is the butterfly-shaped grey matter which
consists of neuron cell bodies, dendrites and axons. The surrounding tissue is the
white matter which is occupied solely by axons and glial cells. Neurons are the
structure and function units in nervous tissue which are capable of generating (from
the cell bodies, dendrites and nodes of Ranvier) and transmitting (axons) action
potentials (AP), whereas, neuroglia cells are supporting cells which are critical for the
survival and function of neurons. Glial cells account for half the total volume of CNS.
They are smaller in size but outnumber the neurons by 5-10 times. The white color
of white matter is due to the lipid-rich myelin wrapped axons. The major functions
of myelin are to insulate axons from the dissipation of electrically charged molecules
and stabilize the mature axons from randomly axon sprouts. Myelin sheath gaps, also
called as nodes of Ranvier, are uninsulated areas, capable of generating AP [8]. AP is
a transit discharge of many positive and negative ions through the cell membrane and
occurs when excitable cells reach a potential threshold. Then the potentials across the
membrane are reversed by opening of voltage-gated ion channels on the membrane.
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AP is transmitted through myelinated spinal cord axons by jumping from one node
to the next one. This conduction pattern is named saltatory conduction.
Axons are arranged symmetrically as nerve bundles or tracts to transmit so-
matosensory and motor orders. Ascending tracts including Dorsal Column Medial
Lemniscus System, Spinocerebellar Tracts, and Anterolateral System, receive sensory
signals from the rest of body and project these eventually to the sensory cortex in
the brain. Descending tracts including Pyramidal Tracts and Extrapyramidal Tracts,
send motor axons from the brain to the lower motor neurons in the cord, and to
the muscles or organs [1]. Injuries to the spinal cord can impair the electrical con-
duction or even block nerve impulse through the damage site(s). It results in the
conduction blockage below the level of the insult. Therefore, the brain is essentially
disenfranchised from the body.
1.2 The pathophysiology of spinal cord injury (SCI)
SCI can happen to grey matter, white matter or both, but the insult most com-
monly occurs at the white matter. The grey matter damage usually leads to the
weakening of the limbs due to the loss of neurons at a restricted vertebral segment.
Since the limbs are innervated by motor neurons from several vertebral segments,
the loss of motor neurons at one vertebral segment causes paresis, or weakening, but
not paralysis [1]. The loss of gray matter is sometimes referred to as central cord
syndrome. The grey matter damage in SCI does not closely associate with significant
behavior loss in patients. Alternatively, SCI-induced paralysis is commonplace when
the white matter is damaged. Injuries on the nerve tracts can destroy the myelin
insulation or tether the axons. The discontinuity of the conduits for electrical con-
duction slows down or even blocks nerve impulses. SCI at the thoracic, lumbar, or
sacral regions results in paraplegia, while at the cervical level, the outcome of SCI is
quadriplegia. Paraplegia is the loss of motor and sensory functions at legs. Quadriple-
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gia is the paralysis at arms, legs and torso. Therefore, the higher the level of SCI,
the greater loss of function a person experiences.
1.2.1 Primary and secondary injury
In most cases, SCI is initiated when the spinal cord is under constant compression
by damaged vertebral columns. Sometimes, the fragmented spine can penetrate the
spinal meninges. The damage to the grey matter, which is more vascularized, results
from the central manifestation of compression from the outside. Thus, cords degener-
ate from the center outwards and it is referred to in the clinic as central hemorrhagic
destruction [9]. The white matter is also crushed and distorted. Complete spinal
cord transection is rare. The localized insult, usually extends less than one vertebral
segment, and is referred as the primary injury. Within hours, the localized damage
can progress beyond the initial zone to neighboring healthy cell producing more tissue
death. The self-propagating cell loss which is often centered by biochemical cascade
is regarded as the secondary injury. In secondary injury of SCI, the disruption of
membrane permeability and the following generation of endogenous toxins, such as
free radicals and aldehydes, can form cycles that induce cellular destructions over
many weeks to months [10].
1.2.2 The lipid composition of animal cell membranes
The cell membrane is a biological membrane, consisting of membrane lipids and
membrane proteins. Membrane lipids are amphiphiles. Driven by hydrophobic in-
teractions between the acyl tails of lipids and other weak forces (hydrogen-bonding
and van der Waals), membrane lipids assemble as membrane lipid bilayers sponta-
neously. The core of the membrane is hydrophobic and the surfaces of the membrane
are polar, surrounded by cytosol or extracellular fluid. Most of molecules and solutes
are not capable of diffusing passively through the membrane due to the hydropho-
bic regions of the cell membrane. The major components of animal cell membrane
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lipids are phospholipids, glycolipids, and cholesterol, with phospholipids the most
abundant. A phospholipid molecule is an amphiphile. The hydrophobic groups are
fatty acid chains, while the hydrophilic components consist of a glycerol or a sphingo-
sine backbone, a phosphate and an alcohol. Due to the polar phosphate headgroups
of phospholipids on the membrane bilayer, the membrane surface carries an over-
all negative charge. Based on the types of fatty acid chains, glycerophosphlipids
can be classified further as phosphatidylcholine (PtdCho), phosphatidylethanolamine
(PtdEtn), phosphatidylserine (PtdSer), phosphatidylinositol (PtdIns) and phospha-
tidic acid (PA). At the cell membrane plasma level, PtdCho is the most abundant
membrane lipid on the extracellular side and it accounts for more than 40% of phos-
pholipids. The PtdCho molecule is a zwitterion which carries neutral charge due to
the anionic phosphate group and cationic choline [11].
1.2.3 The selective permeability of cell membranes
An intact animal cell membrane serves as a selective permeability barrier that
regulates the passage of ions and molecules through the membrane. The resulted
heterogeneous distribution of ions across the plasma membrane produces a voltage
difference, which is called the membrane potential. The resting membrane potential
is established by electrochemical equilibrium mainly via Na+/ K+ pumps and leaking
K+ ion channels imbedded on the cell membrane. In an axon hillock of a typical
neuron, the resting membrane potential is around −70mV which is contributed mainly
by intracellular potassium ions. Calcium ions and sodium ions are tightly regulated
and are mostly excluded to the cell’s exterior space. In a cardiac cell, there is a
25000 times difference of calcium ions across the membrane, which creates a strong
electrochemical driving force for Ca2+ inward flow through the opening of voltage-
gated calcium channels when the membrane is depolarized.
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1.2.4 The role of the membrane distortion in SCI
In SCI, the cell membrane integrity is mostly impaired by mechanical forces. The
distorted membrane is likely the earliest adverse response to primary injury. Me-
chanical forces can damage the integrity of the cell membrane by creating membrane
defects, such as “holes”. For instance, the tapping mode of an atomic force microscopy
(AFM) was used to produce precise punctures through cell membranes in vitro (50
nm diameter, 500 nm in depth). The resulted leakage of cytoplasm out of the soma
through the “holes” slowly led to the collapse of the cell morphology. An ever-growing
pool was formed on the floor of the substrate over a period of 30 min [12].
It was suggested that the influx ions, particularly Ca2+ ions can activate the re-
sealing strategies to block the “holes” by insulted cells spontaneously, if the membrane
defects are limited [13–16]. However, more often, in the traumatic injury, the impact
of unregulated ions is so overwhelming that it can deplete the membrane battery
quickly and result in a conduction block [17]. Without the regulation of ions across
the cell membrane, cells can be randomly excited or shut-down completely through
dysfunctional voltage-gated transmembrane proteins. As a critical messenger ion,
quickly increased intracellular Ca2+ then non-selectively and simultaneously activate
downstream biochemical pathways. Cellular proteins that maintain the mechanical
strength of the cell, such as the cytoskeleton, microfilaments and microtubules, will
be destabilized by increasing Ca2+ which results in the collapse of regular cell mor-
phology. Similarly, cascading down the electrochemical gradient, the influx of large
amount of Na+ ions also trigger the release of the cytoplasmic pool of Ca2+ ions
in the mitochondria which leads to mitochondria dysfunction. Moreover, the mem-
brane disruption leaves cells susceptible to necrotic cell death. The dying necrotic
cell will eventually burst and release deadly intracellular aldehydes, such as acrolein,
into extracellular space, triggering inflammation and tissue swelling [18,19].
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1.2.5 Membrane disruption as the turning point from primary injury to
secondary injury
Membrane disruption is also a critical link between primary and secondary injury.
The mitochondria dysfunction in injured cells leads to unregulated generation of free-
radicals, such as super oxide, hydroxyl ions and hydrogen peroxide. These free radicals
can attack and oxidize plasma membrane lipids of cells. This chemical reaction is
called lipid peroxidation (LPO) [20]. During LPO, membrane lipids are broken down
and chemical aldehyde toxins, such as acrolein and 4-hydroxynoneanal, are generated
as “by-products” [18]. These toxins can freely pass through membranes and attack
cellular membrane and organelle membranes in nearby cells, producing a continuing
process called “bystander damage”, which results in the damage beyond the initial
insult area.
Compression damage in white matter can progress in severity to tissue discon-
nection in some, but not all, spinal cord (or peripheral nerve tracts). The proximal
segments (connected to the cell bodies) may remain intact but are permanently iso-
lated from their target cells. The distal segments of these same axons completely
degenerate and are lost in all mammals. This process is called Wallerian Degen-
eration. Wallerian degeneration was first described by a British neurophysiologist,
Augustus Volney Waller. As a result, the previous impaired electrical conduction
produced by the primary injury is forever lost as secondary injury processes continue.
This process is variable in time. It may take hours to many weeks depending on
many factors such as the severity of the primary injury, the axon’s caliber, whether
it is myelinated or not - to name but a few. It has been demonstrated that quickly
restoring membrane integrity can preserve and enhance cell viability and attenuate
both primary and secondary damage [1, 21–28].
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1.2.6 Reactive gliosis and fibrous scar tissue developments in SCI
When the dura matter, located at the outermost layer of the meninges, is pene-
trated during SCI, the connective tissue elements, mainly fibroblast, can invade the le-
sion. These become knitted with each other through the production of non-functional
extracellular matrix and also walled off by reactive astrocytes to form a multicellular
and dense fibrous scar tissue. This is usually referred to as the fibroglia scar noting
its two main cellular components. When the dura matter is not broken, the scar
is occupied by reactive astrocytes only. The hypertrophic astrocytes produce dense
intermediate filaments, glial fibrillary acidic protein (GFAP), and form a rubbery
membrane at the tips of nerve fibers. Even though, there are disagreements of the
gliosis and fibrous tissue as a possible physical barrier to CNS regeneration [1,29,30],
both inhibitory molecules interfering with axon guidance and disfavoring nerve re-
generation are demonstrated to be closely associated with the harsh environment of
the “scar” tissue. NI-250 and N35 were the first clearly identified myelin associ-
ated inhibitory factors. Other inhibitory molecules are: 1) proteoglycans-chondroitin
sulphate proteoglycan (PSPG)-generated by reactive astrocytes; 2) secreted protein
semaphoring 3 (SEMA3), highly expressed by invading fibroblasts at the core of the
lesion; 3) ephrin-B2 in astrocytes and its receptor EPHB2 , also associated with fi-
broblasts of the fibrous scar tissue; and 4) the slit proteins along with glypican 1
receptor in reactive astrocytes.
1.3 The pharmacological interventions of SCI
The pathophysiology of SCI can lay out several blueprints for pharmacological
strategies to reduce the severity and consequences of SCI. The goals of current re-
search are to facilitate the repair of existing damage and prevent new damage due
to secondary injury in SCI. Promising neuroprotective agents under current inves-
tigations of clinical SCI trials are Riluzole, a sodium channel blocker, Methylpred-
nisolone (MP), a ROS scavenger, Erythropoetin (EPO), a hormone, and Minocycline,
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an anti-inflammatory agent (Table 1.1). However, the application of these therapeutic
agents requires caution due to various side effects, such as infections and hepatotox-
icity. Hepatotoxicity is defined as chemical-induced liver damage (discussed here as
drugs) and is often difficult to diagnose in patients [31]. The liver acts as a “chem-
ical factory” that detoxifies chemicals or drugs which makes the liver susceptible to
chemical-induced toxicity. Other beneficial pharmacological agents investigated in
experimental SCI animal models are summarized in Table 1.2. In order to pass these
drug candidates to more advanced stages of human clinical trials, more investigations
on drug safety need to be done at pre-clinical level. The beneficial effects derived
from studies which are conducted using single type of laboratory animals (almost al-
ways rodents) need to be validated in other species of laboratory animals, because a
drug may affect one species differently from another (Guidance for Industry, Animal
Models-Essential Elements to Address Efficacy Under the Animal Rule).
1.3.1 Restoring membrane integrity by membrane fusion polymers: po-
lyethylene glycol (PEG) and chitosan
PEG
The Borgens research group pioneered the application of polymers to restore in-
jured spinal cord tissues. PEG is a hydrophilic polymer with different molecular
weights (MW) depending on its chain length. PEG is the basis of many laxatives and
PEG 3350 is FDA-approved. Borgens et al. thoroughly investigated the neuroprotec-
tive effects and limitations of PEG in both animal SCI and brain trauma [21–23,45,46].
They reported that brief administration of PEG within 8 hours of SCI can facili-
tate nerve conduction and functional recovery by restoring membrane integrity in
vivo [24]. They also demonstrated that PEG can attenuate the production of ROS-
induced by both compression spinal cord injury and acrolein-mediated PC12 neural
death [25, 28, 47, 48]. On the other hand, the toxicity of PEG administration is also
well established in vivo and ex vivo. The prolonged exposure (more than 5 mins)
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Table 1.1
Pharmacological strategies for SCI in current clinical trials [32].
Agents Functions Trials (Phase) Side Effects
Riluzole
Glutamate receptor [33] and
II and III
Hepatotoxicity [34]









matter and myelin [38]
Minocycline Anti-inflammatory agent [5] III Hepatotoxicity [34]
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Table 1.2
Major neuroprotective agents in experimental SCI studies.
Target Category Agents Limitations
Gliosis tissue and fibrous “scar” tissue
Dystrophic Protein BDNF Modest regeneration [39]
environment neurotrophic NGF fail to overcome myelin inhibition [1]
factors NT3 off-target enhanced neuron functions [40]
PSGS Protein enzyme Chondroitinase-ABC Incomplete digest of GAG chains [41]
Myelin inhibition Small molecule dbc-AMP Not clear [42]
Myelin debris Recombinant protein Rho inhibitor Not clear [43,44]
Membrane defects
Polymers
Polyethylene Glycol High MW viscosity and monomer
(PEG) toxicity [21,22,24,25]
Polymer Chitosan Hemostasis [26]
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of PEG on healthy spinal cord tissues was found to cause axon fusion and cavita-
tion [1]. PEG is not biodegradable and the excretion pathway of PEG is mainly
through kidney filtration. High doses of PEG have the potential to cause kidney
failure. In addition, low MW (such as 300Da) PEG, or the impurity of injected PEG
with monomers, or the breakdown products of long PEG chains, such as monomers
and dimers, can also produce PEG toxicity.
Chitosan
Another polymer investigated in the Borgens group that also has neuroreparative
potential is chitosan, a natural cationic polysaccharide [26,27,49]. Due to the polarity
and biodegradability of chitosan, it is extensively used in many applications, such as
water filtration, food industry, wound management and drug/gene delivery [50–53].
In addition, Cho et al recently reported that chitosan can seal membrane breaches
produced by transection and compression injuries in the white matter of spinal cords.
The main mechanism was suggested through electrostatic interactions between the
amino groups of chitosan and phosphate headgroups of the membrane lipids [26].
1.3.2 Considerations
Many promising neuroprotective agents are based on successful cell and animal
studies. However, the transition from pre-clinical to clinical stage is filled with obsta-
cles, mainly because of the inherent complexity of human body on drug enzymatic
metabolism.
As we know, the therapeutic effect of a drug mainly depends on the local con-
centration at the sites of action. Once a drug enters the human body, the activity
and life-time of the drug are challenged by different physiological systems, simultane-
ously or subsequently: the blood, the immune system, the filtration system, the blood
brain barrier and the digestive tract (based on the route of administration). Fast drug
metabolism or a short-life time in the circulation system results in the reduction of
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the local drug concentration, which can lead to a possibly compromised therapeutic
effect and unnecessary drug accumulation in sensitive organs. However, simply in-
creasing the dosage might not enhance the desired outcome. More commonly, this
could induce side effects in a dose-dependent manner, especially in pre-compromised
organs. When the safety window of the drug is narrow, the side effects can some-
times overwhelm the desired outcome and lead to fatal conditions. 4-Aminopyridine
(4-AP) is such an example. 4-AP is a potassium channel blocker. It was shown to
restore the conduction block in demyelinated nerve fibers in SCI. However, this ther-
apy can induce peripheral vasospasms, which is the most hazardous complication of
this drug [1]. In addition, since most candidate drugs used in CNS Injury are based
on proteins or molecules, (summarized in Tables 1.2 and 1.1), the systemic circula-
tion of these “bare” and “bulk” materials (candidate drugs) in the body makes them
vulnerable for antibody opsonization and phagocytosis. Opsonization describes the
process of non-specific binding of “invaders” (discussed here as therapeutic agents)
with antibodies which can in turn attract the phagocytes for ingestion and destruc-
tion. Phagocytosis as one of the major body innate immune responses protects the
body by direct internalization of the foreign objects for destruction. Phagocytosis is
size dependent and it is sensitive to the object with the size larger than 0.5µm [54].
The initiation of phagocytosis is also enhanced by small contact angles (less than
45◦) [55]. The contact angle is defined as the angle between the average tangential
line at the spreading surface of a phagocyte on an object and the membrane normal
line at the site of attachment. In other words, an object with irregular shape is sus-
ceptible to phagocytosis. One liter of human blood contains about six billion white
blood cells in which macrophages are the most competent phagocytes. Therefore, the
biocompatibility of therapeutic agents in the physiological fluid is highly important.
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1.4 Nanomedicine
Advanced nanomedicine technology brings opportunities for innovative drug de-
velopment and drug delivery methods. Nanomaterials are materials with the size
scale of a billionth part, generally less than a micron [56]. The nano-scale size is
similar as the size of biological molecules - even viruses - which increases the bioavail-
ability and protects nanoparticles from phagocytosis. Moreover, the large surface
area on/inside the nanoparticles (NPs) can be viewed as a great reservoir for small
molecules, drugs, genes and even stem cells. The core materials of the nanoparticles
can be inorganic or organic (like silica and chitosan). Therefore, the functions of the
nanoparticles can vary. For instance, gold nanoparticles were used as contrast agents
for in vivo tumor imaging with photoacoustic tomography technology [57]. Iron oxide
nanoparticles were proven to be highly effective for magnetic resonance imaging [58].
Silica nanoparticles were capable of loading and releasing drugs (hydralazine) in a
time-dependent manner [25]. Nanoparticles are referred as theranostic nanomedicines
when they combine both diagnostic (imaging) and therapeutic (drug delivery) prop-
erties together. For instance, magnetic nanoparticles were used to trace the tumor
location and the induced hyperthermia was used as a treatment to kill tumor cells in
a mouse xenograft model by alternating magnetic fields [59]. The surface functional-
ization of mesoporous silica nanoparticles enabled nanoparticles with both drug/gene
delivery and sensing applications [60]. One successful example of nanomedicine ap-
plication is the FDA approved cancer drug Abraxane, which is a paclitaxel-albumin
nanoparticle. Major nanomedicine studies in CNS are summarized in Table 1.3.
A new generation of nanoparticles enhances the retention of nanoparticles at a
specific group of cells using targeting strategies by attaching antibodies and small pep-




Major NPs’ studies in CNS injury (animal and cell studies)
Nanoparticles





Iron oxide, Optic nerve
Polyethylenimine Molecule-D Rhodamine B transection [61]
Poly-lactic-co-glycolic









PEG SCI compression and
Restoration coating transection, PC12 cells [25]
Silica (with drug) Drug-D Incubation Hydralazine Acrolein-PC12 cells [28]
Magnetic Toxicity and uptake Intravenous Neil red SCI transection [64]
Chitosan Drug-D Incubation Hydralazine Acrolein-PC12 cells [27]
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1.5 Goals of this work
Our previous work showed that brief incubation of damaged spinal cord with
chitosan polymer solution can significantly inhibit the random exchanges of intracel-
lular and extracellular molecules and restore the signal conduction through the injury
site [26].
This work was based off the previous observations, and pushed forward to con-
tinue to investigate the neuroprotective effects derived from intrinsic factors of chi-
tosan polymer. The purpose of this work is to provide insights for the mechanisms
of the neuroprotection by chitosan polymer. Two major factors investigated were
molecular weight (MW) and degree of acetylation (DA). Nanofabrication technol-
ogy was utilized to preserve the neuroprotective effect of chitosan and increase its
performance in physiological fluids. Chitosan nanoparticles were synthesized by an
ionic gelation method. Different parameters were investigated to provide insights on
the mechanisms of nanoparticle formation and optimize the performance of chitosan
nanoparticles. The neuroprotective effect by chitosan nanoparticles in a hydrogen
peroxide challenged cell model was tested. Finally, the signal conduction profiles
of both healthy and compression injured animals were established. The functional
recovery after the administration of chitosan nanoparticle was investigated. In addi-
tion, the affinity of PEG-coated silica nanoparticles at the compression injury sites
of spinal cord tissues was investigated as a parallel study.
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2. AFFINITY OF POLYETHYLENE GLYCOL (PEG) -
SILICA-NPS FOR DAMAGE SITES OF MEMBRANES
AFTER SPINAL CORD INJURY
2.1 Introduction
Spinal cord injury (SCI) is a complex pathological process. It is generally initiated
by a mechanical force and progresses as a secondary injury, primarily via biochem-
ical cascades [10, 66]. Damage to the integrity of cell membranes is a direct and
dangerous consequence of SCI [21–23]. When the lipid bilayer structure is impaired,
the regulated ion gradients across the membrane are lost and leave the cells vulnera-
ble to necrosis. Even though membrane self-repair can be activated by Ca2+ influx,
spontaneous repair often fails to keep pace with the self-propagating and ever en-
larging scope of membrane disruption after traumatic injuries [13,15]. Consequently,
unregulated Ca2+/Na+ influx can lead to structural protein destabilization, reactive
oxygen species (ROS) generation, and subsequent lipid peroxidation (LPO) [15, 67].
Promising strategies for controlling cellular and tissue damages after SCI include neu-
roprotective agents against ROS production, stem cell therapies. Among all therapies,
restoring membrane integrity rapidly and effectively after injury would be critical to
interfering with progressive secondary injury and further deterioration of the tissues
of the central nervous system (CNS) [21–23].
It has been shown that locally applying membrane fusion polymers such as po-
lyethylene glycol (PEG) soon after SCI can reduce cell death, attenuate secondary
injury, and partially restore signal conduction through the region of damage [24,47,48].
PEG is a polyether compound. The degree of polymerization determines the chain
length or polymer MW, which also affect the physical properties of PEG, such as
viscosity, when it is prepared as solution. In high MW PEG, the increased inter-
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molecular interactions result in higher viscosity. Due to its hydrophilicity and low
toxicity, PEG can be used as laxatives, tablet excipients and as well as coupled with
hydrophobic molecules to form surfactants.
PEG is also a well-known cell membrane fusion agent [68–70]. The first PEG
induced membrane fusion was discovered in plant protoplasts in 1974 [71]. Later,
PEG-induced membrane fusion was recognized between different types of cells such
as hen erythrocytes and yeast protoplasts [72]. The mechanism of PEG-induced
membrane fusion was first suggested to be due to a dehydration effect and followed
by a volume-exclusion effect which induces the aggregation of lipids between closely
contact membranes [14, 73]. The dehydration effect by PEG is to exclude water
from the regions of disorganized and disrupted membranes. The volume-exclusion
effect describes the dynamic adaptation of membrane lipids towards the hydrophobic
environment in the regions of disorganized and disrupted membrane by driving the
re-aggregation of the neighboring membrane lipids. According to the fluid mosaic
model of S.J.Singer and G.L. Nicolson (1972), the structure of membrane lipids and
proteins is dynamic [74]. In order to minimize the energy cost and stabilize the
structure, closely contacted lipids are reorganized into single bilayer through lateral
diffusion, aggregation, and re-assemblage of neighboring lipids.
The membrane fusion function of PEG also serves as the basis for each neuropro-
tective effect. Borgens et al. reported that a brief administration of PEG within 8
hours of SCI facilitated nerve conduction and motor recovery in an in vivo study [21].
PEG also attenuated acrolein-mediated PC12 neural death [75]. However, PEG is not
a ROS scavenger. The beneficial effects of PEG are due to the restoration of the mem-
brane integrity. This significantly reduces or eliminates the pathological exchange of
ions and molecules between the cytoplasm and external milieu. This unregulated
exchange is the impetus for ROS production. The routes of administration of PEG
were also tested in topical, intravenous, intraperitoneal, and subcutaneous applica-
tions [21, 22, 45, 46, 76, 77]. All applications provided significant benefit in anatomi-
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cal, physiological, and functional outcomes measured in adult guinea pig models of
SCI [21,22,45,46,76,77].
On the other hand, the toxicity of PEG administration was also investigated both
in vivo and ex vivo. The prolonged exposure (>5mins) of PEG on healthy spinal cord
tissues was found to cause axon fusion [1]. PEG is non-biodegradable and is excreted
from the body via kidney filtration. Therefore, high doses of PEG might increase the
stress of kidney function and potentially induce kidney failure. In addition, low MW
(such as 300 Da) or the impurity of PEG with monomers can produce ethylene glycol
toxicity [78, 79]. The high viscosity in high MW PEG also increases the injection
pressure through syringes during the delivery of PEG solutions [80–83].
Therefore, the administration of PEG inside the human being has to be tailored
to keep the therapeutic effects and minimize the toxicity induced by systemical circu-
lations. Our previous study showed that PEG-functionalized silica NPs (PSINPS) ex-
hibited neurprotective effects on the spinal cord tissues subsequent to experimentally
induced traumatic injuries [25]. The subcutaneous administration of PEG in animals
with spinal cord compression injury also provided statistically significant beneficial
effects on the restoration of somatosensory evoked potentials (SSEP) compared with
saline control treatment groups [22]. The presence of SSEP in post-injury groups
indicates the conduction of nerve impulses through the lesion. To summarize, the
advantages of PSINPs are: (1) the surface areas on the NPs are large and sufficient
to carry enough PEG polymers to produce a therapeutic effect, (2) the segregation
of PEG polymers as nano-scaled packages reduces the viscosity of PEG for the in-
travenous application by increasing the distance between PEG molecules and the
potential toxicity induced by the accumulation of bulk materials in the human being,
(3) the nano-carrier provides new benefits by conjugating with therapeutic drugs or
imaging molecules, (4) PEG coating enhances the biocompatibility and the half-life of
nano-carriers in the body by acting as a stealth layer on the nano-carrier. PEG coat-
ing reduces antibody opsonization by reducing non-specific bindings of nano-carrier
with serum proteins, which in turn decreases the chance of the nano-carrier being
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engulfed and cleared by phagocytes from the blood circulation [25, 84]. Opsoniza-
tion describes the process where a foreign object is marked by antibodies for the
destruction by phagocytes, which are a type of cell protecting the body from harmful
particles.
In this work, we utilized a nanomedicine based labeling system to evaluate the
distribution of PEG polymer on damaged spinal cord tissues. Based on the membrane
fusion capability of PEG polymer, our hypothesis was that PSINPs accumulated in
sites of membrane damage spinal cord tissues. The ex vivo injury model was produced
by a standardized compression injury using a pair of modified forceps on isolated
spinal cord segments. Dye loaded PSINPs were applied to both damaged and intact
cords. The uptake of Dye-PSINPs was evaluated by fluorescence microscopy and
scanning electron microscopy.
2.2 Methods and materials
2.2.1 Spinal cord isolation
All animals used in this study were handled in accordance with, and prior ap-
proval by, the Purdue University Animal Care and Use Committee (PACUC). In
this study, every effort was made to reduce the number and suffering of the animals
used. Adult female guinea pigs (Hartely strain), weighing 300-400g, were anesthetized
deeply with an intraperitoneal injection of a mixture of ketamine (60mg/kg) and xy-
lazine (10mg/kg). Toe-pinch method was used to test the depth of anesthesia. They
were then perfused through the heart with 500ml sterile lactate ringer solution (25◦C)
or until blood completely removed. The vertebral column was excised by performing
a midline incision in the mid-thoracic region and a complete laminectomy. The spinal
cord was extracted and immersed in cold oxygenated Kreb’s solution for at least an
hour to ensure recovery from the surgical procedure before experimentation. The
composition of Krebs’s solution (pH7.2) was as follows: NaCl 124 mM, KH2PO4 1.2
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mM,MgSO4 1.3 mM, KCl 2 mM, NaHCO3 26 mM, CaCl2 2 mM, dextrose 20 mM,
bubbling with 95% O2/5%CO2 throughout the duration of the experiment.
2.2.2 Compression injury ex vivo
A 15-s compression injury was induced using a pair of modified forceps processing
a 0.8mm spacer (Figure 2.1). Previous investigation showed that a complete block
of the compound action potential (CAP) conduction through guinea pig spinal cord
was resulted from the compression injury performed as above [22]. The compression
injury was named as site 0. The proximal areas with a distance of 1cm, 2cm, and
3cm away from the site0 were named as site1, site 2, site 3.
2.2.3 Synthesis and functionalization of TMR-doped, PEG-functionalized
silica NPs (TMR-PSiNPs)
TMR-PSiNPs were synthesized (Figure 2.2). Briefly, the formation of silica NPs
was based on water-in-oil method with sol-gel technology. 4ml 0.3M tetraethyl or-
thosilicate (TEOS), served as a water phase, was slowly added to a mixture of oil
phase chemical solutions with 1h vigorous stirring. The oil phase contained 1.77 mL
of Triton X-100, 1.8 mL of n-hexanol, 7.5 mL of cyclohexane, and 0.5 mL of 1% aque-
ous tetramethyl rhodamine-dextran, where pH was adjusted at 2.0. 60 µL of NH4OH
was added to to terminate polymerization reaction. Silica NPs were precipitated by
acetone and washed with ethanol and acetone several times via centrifugation. Then,
the NPs were dried under vacuum at 100◦C for 12 hr. The surface modification of NPs
by PEG-NH2 (MW 3KDa) was conducted via a reactive schiff’s base linkage. The
pre-hydrolyzed silanol group by 3-(trimethoxysilyl) propyl aldehyde (TPA) provided
an aldehyde group to react with amino group on PEG.
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Fig. 2.1. Schematic illustration of the compression injury to an ex
vivo spinal cord tissue. The top right shows a pair of modified forceps
processing a 0.8mm spacer. The central image illustrates the isolated
spinal cord tissue incubated in the PEG-Silica NP suspension. The
dark spots represent the NPs. The lower left image demonstrates the
compression injury induced by the forceps at Site 0. The red regions
at Site1, Site2, and Site3 are indicated as intact segments with a
distance of 1-cm, 2-cm, and 3-cm away from the compression site 0.
2.2.4 Evaluation of the affinity of TMR-PSiNPs at the damage sites of
spinal cord tissues
Fluorescence microscopy
A 8-cm spinal cord segment was used at each experiment. A 5s constant mechan-
ical compression injury was induced at 2-cm away from one end of the segment by a
pair of modified forceps processing a spacer. Three intact areas were located 1-cm,
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Fig. 2.2. TMR-PSINPs. (a) The illustration of PEGylation of TMR-
doped Silica NPs. The NPs were loaded with 0.1% TMR and synthe-
sized by a reverse-microemulsion method. TPA was used to function-
alize the silanol group on the surface of silica NPs. PEG was coated
through a schiff’s base linkage with aldehyde group immobilized on
NPs. (b-d) TEM images of bare-silica NPs (b), PEGylated silica NPs
(c), and a magnified image of PEGylated silica NPs (d). The fluffy
surface of the silica NPs demonstrated the present of PEG polymers
on the surface. (e) The image of TMR-PSINPs captured with the
Rhodamine channel of a Fluorescent microscopy.
2-cm, and 3-cm away from the compression site (Figure 2.1). The whole cord was
incubated in the TMR-PSINPs solution (1mg/ml) for 15mins in the dark at room
temperature to allow the interaction of NPs with both lesion and intact areas. The
cord was further incubated in the Kreb solution for another 5mins to remove the
loosely attached fluorescence probes on the tissue surface. The cord was carefully
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dissected as 1cm segments with lesion or intact areas exposed to one end. Then the
segments were fixed in 4% paraformaldehyde for 4-5hours in the dark. After fixation,
the segments were embedded in Tissue Tek OCT compound, frozen in liquid nitrogen.
Sections were cut at 50µm thickness using a freezing microtome (Thermo Electron,
Waltham, MA, USA). Then, the sections were visualized by epi-fluorescence on an
Olympus BX61 microscope with a standard rhodamine cube (545nm and 590nm of
excitation filter and emission filter, Olympus). Rhodamine fluorescence images were
captured at a 2x objective. At this magnification, the whole section was captured
within one image. The images were saved for further analysis. All parameters of the
fluorescence microscope were kept constant during the experiment. Quantification
of the fluorescence intensity was measured by using Image J software (NIH). Four
sections or images were randomly recorded from the target zone for each treatment
at each experiment. Triplicates were performed for each treatment. The imaging
zone was defined as the thickness within 1-2mm of the site of lesion or intact area. 12
data points were measured to produce the average intensity value for each treatment.
The florescence intensity of white matter in each section was taken after outlining the
boundary of the white matter manually. The value of the fluorescence intensity was
expressed in arbitrary units, generated from the software.
Scanning electron microscope (SEM)
Spinal cord tissue segments treated with PSINP were fixed in 2.5% glutaraldehyde
at 4◦C overnight. The fixed tissue samples underwent continuous dehydration by
different concentrations of ethanol. The ethanol incubation time was 15-30mins from
30% to 100% ethanol. The tissue can be stored in the 100% ethanol until it was read
to be visualized by SEM. After dried by critical point drying method, the PSINP
imbedded tissue segments were coated with a thin layer of conductive material with
a JEOL JFC-110 ion sputtering (Tokyo, Japan) and the images of samples were
recorded by a JEOL JSM-840 SEM .
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2.2.5 Materials
TMR-dextran was purchased from Invitrogen (Life Technologies). Ketamine and
xylazine were purchased from Purdue Veterinary School Pharmacy. All other chem-
icals used were purchased from Sigma Aldrich (St.Louis, MO). SEM is located at
Purdue Life Science Microscopy Facility. Microtome is located in Center for Paraly-
sis Research (CPR) at Purdue University (Thermo Electron, Waltham, MA). Adult
guinea pigs were purchased from Hilltop and housed at Purdue animal holding facility.
2.2.6 Statistics
All data were represented as means±standard deviation. Statistical analysis was
conducted using one-way ANOVA for comparison among more than 2groups and
Tukey-Kramer Multiple Comparisons test for comparison between experiment groups
(InStatTM software). Values were accepted as being statistically significant difference
if the P value was less than 0.05.
2.3 Results
2.3.1 The Distribution of TMR-PSiNPs at Both Damaged and Intact
Sites Revealed by Fluorescence Microscopy
The distribution of TMR-PSiNPs at both the compression site (site 0) and proxi-
mal intact sites (site 1-3) was captured by epi-fluorescence microscopy and measured
by ImageJ software. Figure 2.3 shows the fluorescence images of spinal cord cross-
sections. At site 0, the morphology of grey matter was distorted by the compression
injury which was not observed in other intact samples. It was found that grey matter
was extensively labeled by the TMR probe in all groups, indicating that PEG-Silica
NPs had a non-specific uptake by neurons of gray matter. However, the TMR in-
tensity in white matter was reduced in all sites, at distance from the epicenter of
the lesion. Figure 2.4 showed the quantitative analysis of the fluorescence intensity
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recorded by fluorescent microscopy. Three animals were used here. Four cross-section
images were randomly selected from the target zone. The fluorescent signal intensity
was recorded solely in white matter, excluding the central gray matter. In sites 1-3,
there was an average of 20% reduction of signal intensity compared with site 0 (In-
jured site). These reductions were statistically significant in both site1 (P<0.05) and
site3 (P<0.01). Similar accumulations of PEGylated silica NPs were found among
intact sites1-3 (P>0.05). When the animal number used for this work was increased
to 5, the reduction of TMR-PSINPs was observed as a function of distance away from
the compression injury regions (P<0.05) (Figure2.5).
Fig. 2.3. The distribution of TMR-PSINPs in both compressed and
intact spinal cord segments. TMR fluorophores stained the regions of
grey matter equally in all samples. The intensity of the red fluorescent
signal in white matter was reduced in intact segments (b-d), compared
to the intensity in white matter of the compressed cord (a). a) The
compressed cord (Injured, site 0), where the morphology of the grey
matter was most distorted by the compression injury. b) Intact cord,
1cm-away from the compression site (site 1). c) Intact cord, 2cm-away
from the compression site (site 2). d) Intact cord, 3cam-away from
the compression site (site 3). Scale bar is 1mm, indicated in (a).
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Fig. 2.4. Quantitative analysis of the distribution of TMR-PSINPs in
both compressed and intact spinal cord segments-1. The fluorescence
probe signals of intact cords in white matter were normalized against
the signals recorded from compressed cords. Data was expressed as a
percent of the intensity at site 0. Site enumeration as above. Com-
pared with site 0, the intensity was statistically significantly reduced
at site 1(P<0.05) and site 3 (P<0.01). At site 2, a reduction of the
intensity of the signal was observed as well, but the significance of the
difference was not reached. (n=3). Data was expressed as mean±SD.
2.3.2 The accumulation of PSiNPs at both damaged and intact sites re-
vealed by SEM
The accumulation of PEG-Silica NPs at both the compression site (site 0) and
proximal intact sites (site 1-3) was evaluated by SEM. Figure 2.6 shows the SEM
images of spinal cord cross-sections. Due to the compression injury, a difference in
morphology was observed between site 0 and the intact sites (site 1-3). The surface
accumulation of dense PEGylated particles was noticed at the compression injury site.
As the distance away from the lesion increased, the deposition of NPs was decreased
respectively. Both individual particles and the aggregation of NPs were observed in
these samples.
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Fig. 2.5. Quantitative analysis of the distribution of TMR-PSINPs
in both compressed and intact spinal cord segments-2. Injured (Site
0) is the site of compression as above. Site enumeration as above.
Compared with injured (site 0), the intensity of TMR-PSINPs was
reduced at site 1, site2, and site3 significantly (P<0.01). Results are
expressed as a percent of the uninjured values ±SD (n=5). **P<0.01,
***P<0.001.
2.4 Discussion
In this work, we addressed the issue of the affinity of PEG for damaged regions
using isolated spinal cord segments. The work was based on beneficial effects of PEG
application induced by the strategy of membrane sealing.
2.4.1 Cell membrane “resealing” and cell functions
“Resealing” of the membrane is critical for a free living cell and multicellular
organisms. It was suggested as an adaptive strategy for early eukaryotic cells to
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Fig. 2.6. Qualitative evaluation of PSINPs in both compressed and
intact spinal cord segments by SEM. Spinal cord segments incubated
with PSINPs were examined at the compression injury, site 0(a) and
the proximal intact sites 1(b), site 2(c), and site 3(d). The dense
accumulation of PSINPs was observed in (a), the compressed spinal
cord sample, whereas uptake of PSINPs was minimized in site 1(b),
site 2(c), and site 3(d), the intact spinal cord segments. Individual
and aggregated NPs were partially indicated with green and yellow
color in post-analysis.
survive in many mechanically challenged environments, after the loss of cell wall dur-
ing the evolution from prokaryotes [13, 15]. The acquisition of endosomal/lysosomal
organelles in a eukaryotic cell may enable the evolution of fusion-based resealing.
The resealing of membrane is common and essential in many mammalian cellular
processes, such as endocytosis, exocytosis, and cell division, where the presence of
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Ca2+is often required and necessary in nucleated cells. The disruption of cell mem-
brane in traumatic injuries might also initiate these self-resealing processes [16, 85].
Based on the size of the wound area, the suggested resealing processes can be: (1)
lateral diffusion and aggregation of the free ends of membrane lipids, if the size of the
wound is smaller than 1nm. (2) exocytosis of lipid molecules at the adjacent intact
membrane regions to reduce the wound areas, if the size is smaller than 1µm. (3)
fusion of local vesicles and exocytosis of membrane batches directly at the wound
areas, which serve as “plugs” at the “holes” of the membrane, if the size is smaller
than 10µm. The time required for these resealing strategies to block the random
exchange of materials across the membrane is size and cell type-dependent, varied
from 30s-90mins. In severe cases, the self-resealing strategy might fail to overcome
the unregulated rapid ion exchange and the ensuing destruction of cellular contents.
2.4.2 The affinity of PSiNPs at the damaged regions of spinal cord seg-
ments
Our previous studies showed that the membrane fusion property of PEG was
preserved in PSINPs which were shown to provide beneficial effects on cell viability
and functional recovery in both ex vivo tissue and animal studies with traumatic
injury models [25]. In this work, we pursued the same line of study and further tested
the affinity of PSINPs at the damage and intact regions of spinal cord segments. Our
results suggested that PSINPs accumulated at the compression injury sites of the
spinal cord tissue (Figure 2.6) and a subtle reduction of fluorophores was observed in
the injury sites compared with the intact sites (Figure 2.5) (P<0.05). However, when
SINPs were administered without a PEG coating, there was no significant difference
of the distributions between injured and intact tissue samples (P> 0.05). Therefore,
it is clear the selective distribution of NPs at damaged regions derived from the PEG
coating. Our additional data of X-ray photoemission microscopy (XPS) evaluation of
PSINPs distribution also agreed with both fluorescence imaging and SEM studies. A
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high peak of Si 2p was generated in XPS surface deconvolution analysis confirming
the existence of PSINPs in the compression injured spinal cord sample, whereas a
similar peak was not observed in intact samples [86].
The affinity of PEG with damaged membranes was also discussed using simpli-
fied membrane models, such as Langmuir monolayers of phospholipids [87]. The lipid
monolayer at the air-liquid interface was compressed to a certain surface pressure (SP)
by applying a lateral pressure. The lipid packing density mimics the outer surface of a
cell membrane when SP is 30 mN/m. The impaired membrane organization was indi-
cated as loosely packed lipids. PEG was suggested to insert into the membrane lipids
at the region with low membrane SP and be expelled out at high SP (for instance, SP
at 46mN/m). The preference of PEG at the damage regions was shown in zwitteri-
onic (diphytanoyl phosphatidylcholine (DPhPC) and dipalmitoyl phosphatidylcholine
(DPPC)) and polar lipids (dioleoyl phosphatidylserine (DOPS)). Similar results were
also observed in the interaction between Poloxamer 188 (P188) with membrane mod-
els [88]. P188 is capable of inserting into the model membrane lipids when SP is
several mN/m lower than the SP of cell membrane bilayer equivalent pressure. When
the lipids are packed tightly, P188 is not stable and excluded from the bilayer struc-
ture. P188 belongs to a class of hydrophilic triblock copolymers. It contains the
hydrophilic chains (PPO) centered with hydrophobic chains (PEO).
2.4.3 Other benefits of PEG coating and PEGylation
PEG and PEG derivatives are also applied as coatings by linking with other chem-
ical groups to enable multi-function capabilities of the conjugates in drug delivery in
nanomedicine [84]. PEGylation is the act of covalently attaching PEG chains on the
surface of other chemical structures, such as peptides, drugs, proteins or NPs (NPs).
PEGylation was first described by Davies and Abuchowsky in the 1970s [89,90]. The
first PEGylation targeted amino groups. Now, the conjugation of PEG to thiol, hy-
droxyl or amide groups are also possible. There are several advantages of PEG modifi-
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cation. PEG modified surface can protect the therapeutic agents from degradation by
proteolytic enzymes, unspecific attachment with antibodies, and phagocytosis by the
mononuclear phagocytic system [91]. Therefore, the circulation period for the agent
is prolonged. PEGylation can also increase the solubility of hydrophobic agents, such
as imaging tracers, and alter the distribution of agents (NPs) in vitro and in vivo,
which results in less toxicity [92, 93]. However, the binding affinity for the target
receptor or enzyme is accordingly reduced [94].
2.4.4 The strategy of fluorescence labeling
In order to trace the distribution of PEG in the biological tissues, PEG polymers
are required to tightly bond with dye molecules. An ideal dye molecule needs to have
large quantum yield which describes the efficiency of florescence process, high pho-
tostability and insignificant toxicity. However, the poor performance of traditional
organic or inorganic dyes in physiological fluid limits in vivo applications. Signifi-
cant advancements in nanotechnology led to new nanomaterial based labeling agents,
such as Au-NP, quantum dots, Lanthanide (Ln3+) NPs [95]. Compared with other
polymer-based NPs, silica NPs have been used widely in bioanalysis and labeling
with less aggregation and little dye leakage [25]. The easy surface chemistry of silica
also enables the conjugation of other functional groups for multi-task activities. Even
though static quenching occurs when a large amount of fluorophores are enveloped
in a nano-sized volume, the benefit of largely enhanced quantum yield (large surface
area) of a dye-doped silica nanoparticle than a single fluorescent molecule is a still
significant gain. Silica nanoparticle also increases the photostability and decreases
the toxicity of loaded fluorophores in the physiological fluid. Therefore, in this work,
PSINPs were used to load fluorophores, TMR to represent the location of PEG poly-
mers in both damaged and intact regions.
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2.5 Conclusion
We constructed PSINPs, enveloped doped with TMR fluorophores. The selective
affinity of TMR-PSINPs at the damaged sites of the spinal cord tissues was proven
by SEM and quantitative fluorescence imaging. In addition, the reduction of PSINPs
accumulation is inversely related as a function of distance from the epicenter of the
spinal cord lesion.
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3. THE NEUROPROTECTION BY CHITOSAN
POLYMER - THE EFFECT OF THE DEGREES OF
ACETYLATION AND THE MOLECULAR WEIGHTS OF
CHITOSAN POLYMER
3.1 Introduction
A polymer is a macromolecule that consists of a number of repeated units (mono-
mers). Based on the sources of polymer, it can be natural (protein and deoxyribonu-
cleic acid (DNA)) or synthetic polymers (synthetic plastics). The application history
of polymer as pharmaceutical delivery systems and biomedical devices has been dated
since the last decade [96]. Even though each medical application requires highly spe-
cialized physico-chemical properties of the polymeric material, good biocompatibility
must be met. Polysaccharides, such as cellulose, dextran, starch, hyaluronic acid,
alginate, chitin and chitosan, display both biocompatibility and biodegradability. In
addition, biodegradable polymers are perfect candidates for therapeutic devices such
as temporary prostheses, scaffolds for tissue engineering, surgical dressings, and drug
delivery vehicles, because of the superiority in in vivo metabolism, availability and
minimum toxicity [97].
A biodegradable polymer is a type of material placed inside a biological system
that will be degraded in biochemical ways at a certain time rate. Both chitin and
chitosan are biodegradable. They are degraded enzymatically by chitinases and chi-
tosanases in bacteria and lysozyme in mammals [98, 99]. The hydrolysis products of
chitin and chitosan are its monomers, N-aceytl-D-gluocosamine and D-glucosamine
(Figure 3.1). Glucosamine is suggested to produce anti-inflammatory, hepatoprotec-
tive, anti-reactive effects.
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Fig. 3.1. The chemical compositions of gluocosamine and aceytl-
glucosamine. The monomer is defined as glucosamine if R position is
occupied by a proton. The monomer is defined as acetyl-glucosamine
if R position is occupied as an acetyl group.
Chitin is the second most abundant polysaccharides in the biosphere, after cel-
lulose. The discovery of chitin is attributed to Frenchman Braconnot in 1811 who
found an alkali-resistant material from fungi [99]. The name “chitin” was derived
from the Greek word “chiton”, meaning cuticle by Odier in 1823, after he obtained
the same material from the cuticle of beetles. The primary structure of chitin is N-
acetyl-gluocosamine. It is also the major component in crustacean shells. Triggered
by the increasing abundant shellfish waste in seafood industry in 1950’s, extensive re-
search targeted at converting chitin from waste to promising biomaterials. However,
the poor solubility in aqueous and organic solutions limits the practical applications
of chitin in industry.
As the principal derivative of chitin, chitosan is a naturally cationic polysaccharide
which highly increases its solubility in a weak acid solution. Chitosan is produced by
deacetylation of its parent polymer chitin with alkali and it naturally occurs in certain
fungi (Mucoraceae). Chitosan was first isolated by Rouget treating chitin with potas-
sium hydroxide in 1859. It was named as chitosan by HoppeSeyler in 1894. Then,
the structure of chitosan was finally solved as a linear copolymer, consisting of β (1-
4) linked 2-acetamido-2-deoxy-β-D-glycopyranose (acetylated glucosamine monomer)
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and 2-amino-2-deoxy-β-D-glycopyranose (deacetylated glucosamine monomer) (Fig-
ure 3.2.).
Fig. 3.2. The chemical compositions of chitin and chitosan. Chitin
is defined when R1 and R2 positions are occupied by acetyl groups.
Chitosan is defined if a part of positions (R1 and R2) is occupied by
protons. The percent can be varied from 0%-100%. n and m represent
the number of monomers in the polymer.
Chitosan has a pKa 6.5. It can be protonated at the deacetylated sites in weak acid
solution. Based on the chemical processing, chitosan is usually defined by two major
characteristics: 1). degree of acetylation (DA) which is the number of the fraction of
acetylated unit per polymer molecule; and 2). molecular weight (MW) which is the
number of sugar units per polymer molecule. The protonation degree of chitosan is
proportional to DA. The higher the DA, the higher amount of charges that chitosan
can carry. In addition, higher MW results in higher viscosity of the suspension of
chitosan. This is due to inter-and intra-molecular interactions, especially hydrogen-
bonds. The morphology tends to be coil-like as well. Ideally, chitin is defined as fully
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acetylated form and chitosan is defined as fully de-acetylated form. In this work,
Chitin is referred as the polymer with DA 100%. Chitosan is the polymer with DA
less than 100%.
Chitosan has become one of the most interesting biopolymers because of its abun-
dant renewable resource and its various biological activities. Due to the active primary
amino groups on the polymer, chitosan can be used as an absorption enhancer, phar-
maceutical excipient, metal recovering agent, hypocholesterolemic agent, film-forming
agent, coagulant, polymeric scaffolds, and wound healing areas [50–53]. Global In-
dustry Analysts, Inc., (GIA) predicted that the global market of chitosan would
reach US$21.4 billion by the year 2015 with a surging demand in agrochemicals and
healthcare fields [100]. Chitosan and its derivatives also have neuroprotective effects
(Table 3.1), mainly contributed by the activity of free primary amino groups. The
electrostatic interactions are suggested to be one of the major mechanisms of neuro-
protection. However there is no consistent opinion on the optimum MW and DA in
terms of potential therapeutic effects by chitosan polymer.
In traumatic spinal cord injury (SCI), the integrity of the cell membrane is directly
compromised by mechanical forces. The animal cell membrane consists of membrane
lipids and trans-membrane proteins and serves as a selective permeable barrier to
regulate the exchange of molecules at both cytosol and extracellular environments.
Phospholipids, glycolipids, and cholesterol are major components of animal cell mem-
brane lipids, with phospholipids being the most abundant. A phospholipid molecule
is an amphiphile. It contains both hydrophobic (fatty acid chains) and hydrophilic
components (a backbone, a phosphate and an alcohol molecule). When the backbone
of a phospholipid is a glycerol molecule, it is called as glycerophspholipid. When the
backbone is sphingoid, the lipid molecule is sphingolipids . The anionic character of
the cell membrane surface is contributed mainly by phosphate headgroups of phospho-
lipids on the membrane bilayer (Figure 3.3). Based on the types of fatty acid chains,
glycerophosphlipids can be classified further as phosphatidylcholine (PtdCho), phos-
phatidylethanolamine (PtdEtn), phos-phatidylserine (PtdSer), phosphatidylinositol
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Table 3.1
In vivo neuroprotective properties of chitosan and chitosan derivatives.











Anti-inflammation Water soluble Chi
or Irritations
Serum Deprivation Inhibiting Apoptosis Water soluble Chi 10% 300K
Acrolein Suppressing ROS Chi, Chi-Nanoparticles 15%-20% 200K [27]
SCI Sealing Membrane Breaches Chi 15%-20% 200K [26]
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(PtdIns) and phosphatidic acid (PA). At the cell membrane plasma level, PtdCho is
the most abundant membrane lipid on the luminal side and it accounts for more than
40% of phospholipids. A PtdCho molecule is zwitterion which carries neutral charge
due to the anionic phosphate group and cationic choline [11].
Fig. 3.3. The illustration of a phospholipid molecule on the cell mem-
brane. A phospholipid molecule is composed of the hydrophilic head
(an organic group, a phosphate group, and a glycerol backbone) and
the hydrophobic tail (fatty acids). The organic groups of a phos-
pholipid can be choline, serine, ethanolamine, and inositol. The cell
membrane is charged negatively overall which is contributed mainly
by the anionic phosphate groups.
A previous study showed that the administration of chitosan successfully inhibited
the exchange of molecules (an endogenous enzyme, lactate dehydrogenase (LDH) and
a fluorophore) between the cytosol and extracellular medium [26]. Since chitosan is
cationic, a possible mechanism was suggested primarily through electrostatic interac-
tions between the cationic amino groups of chitosan and anionic phosphate groups on
the membrane lipids. Consequently, the compromised membrane holes were blocked
and, furthermore, the partial recovery of electrical conduction through the lesions of
isolated spinal cord tissue was also observed, while the absence of response persisted
in control groups. Therefore, the number of amino groups, also referred as charged
density or DA, should play a critical role in the chemical properties of chitosan. In
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addition, Quemeneur indicated the profound effect of MW of chitosan polymers on
the interactions with membrane lipids [101].
In this work, we further investigated the effects of DAs and MWs of chitosan
polymer on specifically its neuroprotective effects. We utilized a standard compression
injury model on isolated spinal cord tissues to study the capabilities of chitosan
polymer with different MWs and DAs. Dye-exclusion and leakage of endogenous
enzyme tests were performed to evaluate sealing by chitosan polymer with different
MWs and DAs. The distribution of chitosan polymer on both damaged and intact
spinal cord segments was also investigated.
3.2 Methods and materials
3.2.1 Spinal cord isolation
We followed the method as described previously (section 2.2.1 on page 21).
3.2.2 Transection and compression injury procedures ex vivo
1cm spinal cord strips were carefully dissected from each isolated spinal cord us-
ing a miniature scalpel-like cutting tool (#10315-12 microscaple). The segments were
randomly divided into two groups: injured-untreated and injured-treated segments.
Two types of injury models were used in this study: compression injury and tran-
section injury. After additional incubation of dissected segments in Kreb’s solution,
the compression injury was induced by a 15s constant mechanical compression at the
center of each segment by a modified forcep processing a spacer. The transection
injury at ends of each segment was a requisite of the initial dissection. Therefore,
no further incubation was performed. In the injured-treated group, samples were
incubated with different DAs (0%, 10%, 20%, 100%) and MWs (oligo-chitosan 5kDa,
low-chitosan 100kDa and medium-chitosan 200kDa) of chitosan aqueous solutions
(Table 3.2). The injured-untreated samples were incubated in a freshly prepared
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Table 3.2
Chitosan polymer with different DAs and MWs.
# Abbreviation Chitosan(Chi) Samples DA(%) MW(Da)
MW
1 Low Low MW Chi
15-25
100K
2 Medium Medium MW Chi 200K
3 Oligo Oligo MW Chi 5000
DA
4 DA0 DA0%Chi 0
5 DA10 DA10%Chi 10
6 DA20 DA20%Chi 20
7 DA100 DA100%Chi (Chitin) 100
phosphate-buffer saline solution (PBS). 0.1% (w/v) chitosan solutions were prepared
in 1% acetic acid and underwent overnight magnetic stirring to achieve a complete
dissolution. All solution samples were bubbled with 95% O2, 5%CO2 throughout the
duration of the experiment.
3.2.3 Detecting membrane integrity using a biochemical assay: Lactate
Dehydrogenase (LDH) cytotoxicity assay
A large endogenous enzyme, Lactate Dehydrogenase (LDH, 140 kDa) was used
as a membrane breach indicator. The leakage of this large enzyme into the extracel-
lular space was a gauge of how severe such breaches were. The reduction of nicoti-
namide adenine dinucleotide (NAD) to NADH by LDH in extra-celluar medium can
be specifically detected by colorimetric assay at 450nm. The compression injury was
performed on equally weighted fresh spinal cord strips using a modified forceps pro-
cessing a spacer. Then, segments were treated immediately with different DA and
MW chitosan aqueous solutions and PBS solutions (negative control) respectively
for 15 mins. After rinsing with PBS solution for three times to remove any leaked
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LDH extra-cellularly, spinal cord strips were incubated in 1ml fresh PBS solution
for additional 45mins to allow LDH leakage from un-repaired membrane breaches.
600µl bathing solution was tested using the TOX-7 kit (Sigma-Aldrich, Inc, USA).
The absorbance was read at 490nm and 690nm using a multi-well plate reader on a
spectrophotometer (plate reader). The final value was calculated by subtracting the
background value (at 690nm) from the primary wavelength measurement (at 490nm).
Six replicates were applied in this study.
3.2.4 Detecting membrane breaches using fluorescence microscopy with
a Tetramethylrhodamine (TMR) fluorophore
we used a membrane impermeable fluorescent dye, tetramethylrhodamine (TMR)-
dextran (10kDa), to indicate the degree of membrane damage and fluorescent micro-
scope to measure fluorescence intensity. Transection injury was used since this would
be the most extreme test of membrane sealing-even though transection of white or
gray matter is clinically uncommon. Transection was performed on 1-cm segments
of spinal cord strips. The damaged strips were immediately treated with 0.1% (w/v)
different DA and MW chitosan aqueous solutions and PBS solution, respectively for
15mins. Then, all segments were transferred and incubated in 0.1%TMR-dextran
solution for 15 mins in the dark. After rinsing with 0.1 mol/L fresh PBS solution
three times, samples were fixed in 4% paraformaldehyde for 5h at 4◦C in the dark.
After fixation, the segments were embedded in Tissue Tek OCT compound, frozen
in liquid nitrogen. Sections were cut at 50µm thickness using a freezing microtome
and visualized by epi-fluorescence on an Olympus BX61 microscope with a standard
rhodamine cube (excitation filter, 545nm and emission filter, 590nm, Olympus). Rho-
damine fluorescence images were captured at a 2x objective. At this magnification,
the whole section was captured within one image. The images were saved for further
analysis. All parameters of the fluorescence microscope were kept constant during the
experiment. Quantification of the fluorescence intensity was measured by using Im-
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age J software (NIH). Five sections or images were randomly selected from the injury
zone for each treatment at each experiment. Six replicates were conducted for each
treatment in this test. The injury zone was defined as the area within 1-2mm of the
exact plane of transection. 30 images were measured to produce the average intensity
value for each treatment. The fluorescence intensity of white matter in each section
was taken after manually outlining the boundary of the white matter manually. The
value of the fluorescence intensity was expressed in arbitrary units, generated from
the software.
3.2.5 Tracing the locations of chitosan polymer (DA0) using fluorescence
microscopy with a fluorescein Isothiocyante (FITC)-dextran fluo-
rophore
In order to trace chitosan polymer in damaged and un-damaged spinal cord strips,
fluorescein isothiocyanate (FITC)-labeled chitosan DA0 was used to identify the loca-
tion of chitosan in tissue segments. FITC-chitosan conjugation was prepared accord-
ing to the method of Qaqish et al. [25,102]. The procedure was as follows : 1%(w/v)
chitosan DA0 was dissolved in 0.1M acetic acid by magnetic stirring overnight. 0.1%
FITC in methanol was slowly added to the dissolved chitosan solution. The isothio-
cynate group (N=C=S) reacted with the primary amine group (-NH+3 ) of the chitosan
polymer to form chitosan-FITC conjugation (Figure 3.4).
We allowed the reaction to proceed for 1h in the dark at room temperature.
Then FITC conjugated chitosan solution was treated with 0.1M sodium hydroxide
solution. The precipitation was formed at the bottom and collected by washing with
de-ionized water for at least 3times to remove any free FITC molecules from the
mixture. The polymer then was air-dried and stored in-20◦C for further applications.
It was documented that 2.3% of the amino groups of chitosan were modified in this
reaction without altering the actual basic structure of the polysaccharide which was
determined by elemental analysis. 0.1% FITC-chitosan solution was freshly prepared
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Fig. 3.4. The illustration of the conjugation of FITC-chitosan. A
thiourea bond is formed between the isothiocyanate reactive group
(-N=C=S) of a FITC molecule and the amino-group of chitosan poly-
mer.
in PBS. The compression injury was performed in the middle of isolated spinal cords
as describe. The intact segments located 2cm away from the compression site were
served as self-controls. The whole cord was immediately incubated in the FITC-
chitosan solution for 15mins in the dark to allow the sufficient fluorescence labeling
at the potential areas. Then the cord was rinsed with Kreb’s solution for three times
to remove any free FITC-chitosan extracellularly. 1-cm segments were dissected from
the injury site and intact sites and fixed in 4% paraformaldehyde for 5hrs at 4◦C in
the dark. The methods for the fixation and epi-fluorescence quantification were the
same as described above in method of TMR. The difference is that the excitation and
barrier wavelengths for FITC were 490 and 520nm respectively. Five replicates were
used in this study.
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3.2.6 Chemicals and reagents
TMR-dextran and FITC-dextran were purchased from invitrogen (life technolo-
gies). Chitosan (DA0%, DA10%, and DA20%) was purchased from CarboMer Inc.
Chitosan (oligo lactate, low, medium MW and chitin), LDH cytotoxicity assay kit
and all other chemicals used were purchased from Sigma Aldrich (St.Louis, MO).
Microtome was purchased from Thermo Electron (Waltham, MA). Olympus BX61
microscope is located at Center for Paralysis Research (CPR) at Purdue University.
#10315-12 microscaple was purchased from fine science tools (Foster City, CA).
3.2.7 Statistics
All data were represented as means±standard deviation (SD). Statistical analysis
was conducted using one-way ANOVA (SAS 9.2, SAS institute inc., NC, USA). The
comparison between untreated (PBS) and treated (different DA and MW chitosan)
groups were subjected to Dunnett’s test. The comparison among different chitosan
treatment groups were subjected to Tukey’s test. Values were accepted as being
statistically significant difference if the P value was less than 0.05.
3.3 Results
Membrane permeability with treatments of different DA and MW chitosan was
evaluated by TMR dye exclusive test and LDH assay.
3.3.1 The inhibition of TMR uptake in transection injured spinal cord
by chitosan polymers
Data was normalized by the value of PBS groups and presented as decimals,
where 1 was equivalent as 100%. Strong fluorescence intensity of TMR in controls
indicated the intensive uptake of fluorophores through the compromised membrane
at the damaged tissue sections (Figure 3.5). In contrast, the fluorescence intensity
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in groups with chitosan treatments decreased significantly regardless of MW and DA
(P<0.05) (Figure 3.6). Except for DA100, more than a 20% decrease of fluorescence
intensity was observed in other chitosan treatments (P<0.01). However, no obvious
DA or MW dependent effect was observed (P>0.05).
Fig. 3.5. The fluorescence intensity of TMR uptake after transection
injury and its inhibition by different chitosan treatments. (A) Fluores-
cence intensity of TMR uptake in a cross-section of spinal cord given
transection injury with PBS treatment (control). (B-H) Cross-section
graphs showing different degrees of decreasing fluorescence intensity
of TMR labeling in transected spinal cord with chitosan treatments.
(B) Transection injury with DA100 treatment. (C) Transection in-
jury with DA20 treatment.(D) Transection injury with DA10 treat-
ment.(E) Transection injury with DA0 treatment.(F) Transection in-
jury with Low MW treatment. (G) Transection injury with Medium
MW treatment.(H) Transection injury with Oligo MW treatment.
3.3.2 The inhibition of LDH leakage at the compression injured spinal
cord by chitosan polymers
The membrane sealing effect of chitosan was further confirmed by the inhibition
of the leakage of the intracellular enzyme Lactate Dehydrogenase (LDH) (Figure 3.7).
The signal intensity was proportional to the amount of LDH present in the bathing
solution and inversely related to the condition of the membrane. More than a 60%
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Fig. 3.6. Quantification of normalized fluorescence intensity of TMR
uptake as a function of chitosan treatments. The fluorescence in-
tensity in PBS group used as the control. Note that all chitosan
treatments significantly decreased the fluorescence intensity of TMR
uptake following the transection injury, *P<0.05 , ** P<0.01 (Dun-
nett test). N=6.
decrease of the signal intensity with the treatments of all chitosan strongly indicated
the sealing effects of chitosan (P < 0.05). Similar to the Tetramethylrhodamine
(TMR) test, we did not observe any correlation with the result and the composition
(MW and DA) of chitosan.
3.3.3 The distribution of FITC-chitosan polymers in both intact and com-
pressed spinal cord segments
To investigate the affinity of chitosan polymer at damaged tissue, the intensity of
FITC-chitosan was measured in both compressed and intact spinal cord segments. A
significant difference of intensity of FITC-Chi (DA0) labeling between the compression
regions and intact regions was not detected (P>0.05) (Figure 3.8).
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Fig. 3.7. Quantification of normalized fluorescence intensity of LDH
leakage as a function of chitosan treatments. The fluorescence inten-
sity in PBS group was used as the control. Note that all chitosan
treatments significantly decreased the fluorescence intensity of LDH
leakage following the compression injury, *P<0.05 (Dunnett test).
N=6.
Fig. 3.8. The distribution of FITC-Chitosan on injured (compression
injury) and intact spinal cord segments. No obvious difference of
the labeling of FITC-Chitosan was observed between the injured and
intact cords. (A). The cord with the compression injury. (B). The
cord without the compression injury.
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3.4 Discussion
3.4.1 Membrane resealing mechanisms
Membrane resealing can be achieved through different mechanisms based on the
size and properties of the components that interact. When the size of the membrane
disruption is relatively small, rapid membrane resealing can be accomplished through
the lateral diffusion of continuous bilayers. The exposure of hydrophobic domains of
membrane to the physiological fluid creates an energetically unfavorable area which
acts as a driving force to induce the spontaneous aggregation of neighboring mem-
brane lipids via hydrophobic interactions and hydrogen bondings. In nucleated ani-
mal cells, Ca2+ influx triggered-exocytosis is a key step in the membrane self-sealing.
Membrane lipid molecules can be inserted at the continuous bilayer which indirectly
reduce the size of the “hole”. In the case of the larger “hole” in the membrane, a
patch of lipids are accumulated and fused together at the disrupted region to block
the random exchange of materials across the membrane.
Surfactant polymers such as polyethylene glycol (PEG) and Poloxamer 188 (P188)
are well-known as membrane fusion agents. PEG is a hydrophilic molecule. Each
ethylene oxide unit of PEG molecule typically react with 2-3 water molecules [103].
By associating with water molecules, PEG brings adjacent membrane lipids into close
physical contact which results in the re-organization of membrane lipids via hydropho-
bic interactions. On the other hand, P188 is an amphiphilic macromolecule. It mimics
behaviors of phospholipids and is incorporated into membrane structure at the low
packing density of lipids. Chitosan is a cationic polysaccharide. Chitosan is suggested
to interact with membrane lipids by electrostatic interactions between the free pri-
mary amino groups and the negatively charged phosphate groups. The insertion of
chitosan polymer at the bilayer is also indicated via hydrogen bonding and hydropho-
bic interactions with acyl chains.
Our results revealed that chitosan indeed functioned as an important intervention
in acute spinal cord injury, regardless of its DA and MW. Specifically, the TMR and
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LDH study confirmed the significant effect of chitosan on inhibiting i.) the intrusion
of an exogenous applied dye into damaged spinal cord cells (P<0.05); ii.) as well as
escape of a large endogenous enzyme LDH.
3.4.2 The effect of degree of acetylation (DA)
The different DA represents different strengths of electrostatic interaction between
the cationic chitosan and anionic lipids. Specifically, the lower the DA, the higher the
number of positive ions a chitosan molecule carries. In turn, the higher concentration
of surface charges on chitosan enables a more extended conformation due to electro-
static repulsion among charged amines on the chitosan backbone. Therefore, the po-
larity of the molecules is greatly enhanced. Since the lipid head-groups are negatively
charged, molecules with lower DA might have a greater opportunity to diffuse close to
the membrane breaches, and thus adsorb and seal the membrane through electrostatic
interactions. This mechanism is consistent with previous studies in which chitosan
polymers incorporated with artificial membrane films and vesicles. These physical
attractions and interactions were a result of membrane adsorption [101, 104–106].
Our data however, did not reveal a hint of an improvement in function of chitosan
when the DA is decreasing. Possible reasons might be due to (1) the concentration
of chitosan polymer was too high which masked the DA effect, since the available
binding sites on the membrane might be over-saturated with chitosan polymer, (2)
the neuroprotective effect of chitin might suggest a different mechanism other than
electrostatic interactions with the membrane. However, those hypothesis need further
tests to prove.
3.4.3 The effect of molecular weight (MW)
Here, equivalent sealing effects using different MW chitosan treatments was sug-
gested in both TMR and LDH tests, and in both transection and compression ex vivo
injury models. Based on the fact that different MW chitosan in our study shared a
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similar DA, one possible reason for the consistency of data found in different MW chi-
tosan treatments might be the predominant role of DA over chitosan MW in initiating
membrane repair. The chitosan bioactivity on the membrane lipids was suggested not
only due to the electrostatic interactions [104]. A similar result is also observed in
the zeta-potential evaluation of the influence of different MWs of chitosan on mem-
brane adsorption [101]. The data shown in Figure 3.6 reveals that all tests showed a
statistically significant reduction in TMR fluorescent intensity. There was little differ-
ence between them however - with the exception of DA100 which revealed a possible
lower capability for sealing, but this difference did not reach statistical significance.
The MW of chitosan is closely related with the morphological structure of chitosan
presented in the aqueous solution. Typically, the two most common structures are
1.) rope-like and 2.) coil-like polymeric shapes. The most likely shape in an oligo-
chitosan solution would be rope-like due to the relatively few numbers of monomers
existing in the chitosan. The less folded main chains of this polymer require less
energy to diffuse close to the cell membrane and fit near or into its breaches. MW is
also proportional to the viscosity of the aqueous solution, which reflects the hydrody-
namic diameter of chitosan molecules; refer back to Figure 3.7 and Figure 3.6 [107].
The degree of the intermingling entanglement of chitosan polymer is proportional to
the chain length, in other words - the MW. Considering the higher MW of Medium
chitosan which is 40 times the size of the oligomer, this might result in the reduced
mobility of the polymer. This is likely to enhance polymer adhesion by increasing the
contact area between chitosan molecules and lipids [108]. However, our results did
not show the differences of MW induced function of chitosan based on dye exclusion
(TMR) and protein leakage (LDH) tests.
3.4.4 The effect of targeting
In our study, Chitosan (DA0) polymers were covalently linked with FITC fluo-
rophores. The distribution of chitosan polymer (DA0) at both damaged and intact
53
regions of spinal cord tissues was represented by the localization of FITC signal.
A significant difference of the distribution of chitosan polymer (DA0) was not de-
tected between the damaged and intact regions (P>0.05). Similar conclusions were
suggested in the interaction of chitosan polymer with membrane models, such as
Langmuir films [104]. Even though chitosan polymer is not surface active, it can
interact with phospholipid monolayers through electrostatic interactions, hydrogen-
bonding and hydrophobic forces [104–106]. Based on the packing density of the
phospholipids, chitosan can either insert between membrane lipids or attach on the
subsurface of the monolayer. However, our result was shown to be inconsistent with
the previous report which indicated the affinity of chitosan polymer at the sites of the
compromised membrane lipids in Cho’s work [26]. The disagreement of the targeting
of chitosan polymer at the sites of the compromised lipids might be due to using
chitosan polymers with different MW and DA. In order to illustrate the preference
effect of chitosan polymer on compromised membrane lipids, further test needs to be
developed.
3.4.5 Restoration or disturbance of cell membrane
The interaction of chitosan polymer with membrane lipids is confirmed by both
model and biological membrane lipids [105, 106]. The neuroprotective effects of chi-
tosasn (nanoparticles) observed in PC12 cells, isolated spinal cord tissues and whole
animals studies were suggested to be mediated through membrane restoration [27].
Other neuroprotective effects of chitosan are also observed in applications (Table
3.1). On the other hand, the strong binding capability of chitosan polymer with
model membrane lipids which were “squeezed” at high lateral pressure suggested
the potential of membrane incorporation or even disturbance among tightly packed
lipid molecules [105, 106]. The disturbance of chitosan on cell viability, presumably
through membrane disturbance, was observed in high concentration (>1mg/ml), cell
types (primary cardiomyocytes), and incubation period (>24hours) (data not shown).
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Chitosan is also suggested to be used to “digest” bacteria cells by interacting with
phosphoryl groups of E.Coli [109]. In addition, the amino groups on chitosan poly-
mers can interact with blood cells and initiate haemostasis [110]. Chitosan patches
have also been developed to quickly stop the bleeding. Therefore, the beneficial ef-
fect of the systemic circulation of chitosan polymers might be counteracted and the
unnecessary interactions with serum protein might lead to the quick clearance by
phagocytosis. Chitosan derivatives and chitosan based nanoparticles are developed
to increase the solubility in the physiological conditions, reduce the hemostasis effect
and other side effects based on bulk materials.
3.5 Conclusion
Chitosan reduced the exchange of large endogenous enzymes and fluorescent probes
across the membrane damage. A significant difference of DA and MW dependent seal-
ing effects of chitosan was not detected in the isolated spinal cord segments. A signif-
icant difference of affinity of chitosan at damaged or intact tissues was not observed
as well.
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4. INVESTIGATING AND OPTIMIZING THE
SYNTHESIS OF CHITOSAN NANOPARTICLES
(CHI-NPS)
4.1 Introduction
Nanomedicine is the application of nanotechnology to medicine. Advanced nano-
medicine technology brings opportunities for innovative drug development and drug
delivery methods. Medicinal nanoparticles (NPs) are constructed at the size scale of
a billionth part, generally less than a micron. Why does the size of particles matter in
medicine? The size of NPs is similar to the size of biological molecules - even viruses
- which increases their biocompatibility and reduces the chance of being phagocy-
tized [56]. Phagocytes, such as neutrophils, monocytes, and macrophages function
as part of the innate immune system. Phagocytosis is an endocytosis process where
phagocytes engulf and destroy any foreign objects in the body. Phagocytosis is sen-
sitive to objects with a size larger than 0.5µm [54]. NPs with 10-500nm sizes are
suggested to remain in the circulation for an extended period of time with the intra-
venous administration [111]. Objects with irregular morphologies can also enhance
the initiation of phagocytosis [55]. Materials with nano-structures also exhibit fun-
damental different properties from simple chemicals and these unique characteristics
are not derived from the elemental composition alone. To name a couple of exam-
ples, carbon nanotubes and “quantum dots” or nano crystals. Carbon nanotubes
have unique and remarkable electronic and mechanical properties which give rise to
many applications: flat panel displays, gas storage devices, conduction paints and
others [112]. Semiconductor “quantum dots” are particles with nanometer scale and
capable of emitting size-tunable light. The light emission is significantly brighter
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and more resistant to photobleaching than other dyes (organic dyes and fluorescent
proteins) [113].
There are many advantages of using nanocarriers in drug delivery [56]. Nanocar-
riers with large surface/volume ratios can serve as a great reservoir for drugs, genes
and stem cells. The releasing profile can also be tailored according to the physico-
chemical properties of the nano-carriers. In addition, packing therapeutic compounds
into small (nano-scale) “envelopes” preserves the activity of the compounds from op-
sonization which in turn suppress opsonization-induced phagocytosis and increase the
retention time of the drug (with the nano-carrier) in the blood circulation [114–116].
Opsonization describes the process that antibodies label the foreign objects for de-
struction by phagocytosis. Nanocarriers can also enhance the solubility of hydropho-
bic drugs in physiological fluids. The affinity of nanocarriers with different types
of cells can be modified by attaching targeting moieties. For example, AP peptides
were linked on the glycol chitosan NPs to direct the sufficient accumulation of NPs at
the tumors [117]. Hyaluronic acid (HA) acted as targeting molecules for cancer cells
where HA receptor CD44 was overexpressed on cancer cells [118]. Folic acid-NP con-
jugation was developed to induce folate receptor-mediated cancer cell specific gene
delivery [119]. Interleukin-4 receptor binding peptide was successfully attached on
the glycol chitosan NPs to increase the retention of the NPs at the tumor site [117].
Therefore, the increasing accumulation of NPs on defined groups of cells minimizes
non-specific binding induced harmful side effects.
Nanomedicine can be developed as either a “permanent” nanodevice which acts as
a supportive structure, such as artificial heart valves, or a “temporary” nanodelivery
system for diagnostic, therapeutic, or theranostic purposes. Theranosis describes the
combination of diagnostic and therapeutic modalities by one system for the treat-
ment of the disease. Based on the purpose of the applications of the nanomedicine,
the choices of nanomaterials are varied. NPs are developed based on quantum dots,
gold, silver, iron oxideNPs (imaging), liposomes, carbon nanotubes, fullerenes, silica,
polyethylene glycol, chitosan (drug delivery), and their composites (Theranosis) [56].
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The “permanent” nanodevices require nanomaterials with superior mechanical prop-
erties to counteract the fatigue or collapse of the material in the body long term.
Whereas, the “temporary” delivery system, commonly implemented by NPs, requires
an exit strategy for the excretion of nanomedicine from the human body after drug
delivery. Meanwhile, the toxicity of both the accumulation of nanomaterials and
the generated by-products during the process of the enzymatic metabolism of the
nanomaterials needs to be minimized.
The next question is why do biodegradable materials matter in therapeutic NPs?
A biodegradable material is a type of material that when placed inside a biological
system will be degraded via biochemical pathways at a certain time rate [99]. Using
biodegradable nanomaterials as drugs or drug delivery systems is the most ideal
strategy for combining multiple goals in current medicine research and development,
as introducing “biodegradable foreign materials” inside the human body causes no
stress or harm [97]. The journey of a biodegradable nanomaterial inside the human
body is to perform the therapeutic task by delivering the content in a quantized way,
to be “digested” and excreted as harmless by-products or residues out of the body.
Chitosan is a naturally cationic polysaccharide. It is a biodegradable polymer
in nature and is suggested to be degraded by hydrolases, lysosomes in the human
body. Chitosan has a variety of biological functions. It can be used as a membrane
“fusion” agent, an absorption enhancer, pharmaceutical excipient, metal recovering
agent, hypocholesterolemic agent, film-forming agent, coagulant, polymeric scaffolds,
and wound healing agent [50–53]. Due to the flexible mechanical properties, it can
also be processed into different forms, such as: film, hydrogel, and tablets. However,
the biological applications of chitosan face a few obstacles. With a pKa of 6.5, the
solubility of chitosan in physiological condition (pH7.3) is greatly reduced. Hemostasis
can also be induced by the interaction between the primary amino groups with blood
cells [110,120].
As a biodegradable polymer, chitosan is one of the popular candidates for nan-
odelivery or NP applications [117]. The primary amino groups of chitosan can be
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masked by reacting with anionic molecules to form Chitosan nanoparticle (Chi-NPs)
complexes. Meanwhile, the solubility of chitosan polymer is also enhanced. The ma-
jor methods of chitosan nanoparticle formation are summarized in Table 4.1. Among
all, the ionic gelation method is suitable for biological applications where no harsh
chemicals are involved [121,122]. It is based on the electrostatic interactions between
cationic amino groups of chitosan and anionic groups of participants, such as triphos-
phate (TPP) and dextran sulfate (DS). Chi-NPs have shown neuroprotective effects
on PC12-cells which were challenged with acrolein, an endogenous aldehyde generated
highly after neurotrauma [27]. Chi-NPs are also capable of carrying and delivering
different types of therapeutic drugs, for instance anticancer drugs (paclitaxel, cis-
platin, docetaxel, and camptothecin), aldehyde-scavenger (hydralazine), anti-tumor
peptides and genes [27,123–126].
The major characteristics of nanomedicines are size and zeta-potential. The hy-
drodynamic size is more closely associate with the behavior of NPs in a biological
fluid system which includes both the solvent layer and the dynamic layer. The sol-
vent layer is the immobilized water on the surface of the bare NPs due to the hydration
effect that includes hydrogen-bonding with water molecules. The dynamic layer is
due to the thermal motion of submicron molecules, which is also referred as Brow-
nian motion. The zeta potential describes the net effect of surface charges that NP
carriers and the adsorption of counter-ions at the hydration layer of the NP. The
surface charges of dried bare NPs are determined by the surface chemical properties
of NPs, which also affect the distribution of ions in the medium. The accumulation
of counter-ions on the surface of the NPs leads to the formation of electrical layers.
By definition, zeta-potential is the potential at the surface of the hydrodynamic layer
where ions are associated with the movement of NPs Figure 4.1. The magnitude of the
zeta-potential and size indicate the potential stability of the NP suspension. A stable
colloidal system will generally have a zeta-potential of ±30mV or greater. Systems
with zeta potentials less than that, may be stable, however, this is not certain.
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Table 4.1
Methods of chitosan nanoparticle (Chi-NPs) formation. Methods based on chitosan derivatives are not included.
Methods Pros Cons
Emulsion
Broad Size Range >200nm
Harsh crosslinking agents
cross-linking (glutaraldehyde)
Coacervation Narrow size range (adjusting the
Cross-linking agents (drug loading)
precipitation nozzle size and air pressure)
Spray-drying Microparticles Not for NPs formation
Emulsion-droplet High loading efficiency Loading efficiency
Coalescence (without cross-linking agents) inversely affected by size
Ionic gelation Mild and simple (no harsh chemicals)
Reverse micellar Narrow size range Need surfactants
Sieving Microparticles (500-700µm) Not for NPs formation
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the surface of the NP.
Fig. 4.1. The illustration of zeta-potential. A nanoparticle (NP) is
shown to be incubated in the buffer solution. (a) Surface potential
indicates the potential at the surface of the NP. If the surface potential
of a NP is negative, it means that the NP carries anionic groups, such
as RCOO-. (b) Stern potential indicates the potential at the stern
layer. Due to the electrostatic interactions, counterions (cationic ions)
in the buffer solution accumulate at the hydrated surface of the NP
and these counterions tightly bind with NPs. As the distance from
the surface of the NP is increasing, the attraction force between ions
in the solution and the NP is decreasing. (c) Zeta potential indicates
the potential at the slipping plate (next to the Stern layer) where the
ions in the buffer solution are associated with the movement of the
NP.
In this work, we synthesized and optimized the formation of ChiNPs based on
the ionic gelation method. We formed two types of ChiNPs, namely Chi-TPPNPs
and Chi-DSNPs. We measured the hydrodynamic size and zeta-potential during
different pH and ionic strength environments to investigate the stability of NPs.
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Since measurements of the size and zeta potentials do not guarantee NP formation,
we used transmission electron microscopy to study the morphology changes of NPs
with different preparation factors.
4.2 Methods and Materials
4.2.1 Chi-NPs prepared by an ionic gelation method
Chitosan nanoparticles were prepared using an ionic gelation method. The as-
sembly relied on the electrostatic interactions between cationic chitosan polymer
(200kDa) and anionic molecules chitosan-dextran sulfate (DS)(10kDa) and triphos-
phate (TPP) (387Da). The polymer reaction was highly susceptible to the pH change
and dust accumulation. All reaction glasswares were autoclaved before sample prepa-
rations. Two types of chitosan nanoparticles were prepared in this study, chitosan-DS
nanoparticles (Chi-DSNPs) and chitosan-TPP nanoparticles (Chi-TPPNPs). 0.1%
chitosan was dissolved in 1% acetic acid solution and stirred overnight to achieve
the complete dissolution and homogeneous distribution. 0.1% DS and 0.05% TPP
in de-ionized water were freshly prepared and filtered through 0.45µm sterile syringe
filters. DS or TPP solution was added dropwisely into chitosan solution under mag-
netic stirring with a rate of 2-3s/drop for 1h. The volume ratio were 5:3, 5:5, 5:8.5
for chitosan-DSNP and 5:1.5, 5:2 for chitosan-TPPNP formations. For DS-chitosan
formation, the solution turned cloudy when the volume ratio was above 5:3. For
TPP-chitosan formation, the solution was clear throughout the experiment. The
nanoparticle solutions were kept in 4 ◦C until further analysis or experiment.
4.2.2 The purification of Chi-NPs by membrane dialysis
Regenerated cellulose dialysis membrane (300kDa) was soaked and rinsed with
de-ionized water for 15mins to remove the remaining sodium azide. ChiNPs were
carefully pipetted inside the membrane pocket. The pocket was sealed tightly with
62
dialysis closures on both ends. The dialysis membrane was placed in nano-pure
de-ionized water with gentle magnetic stirring. The ratio of the loading solution
and dialysis buffer was at least 1:100 to achieve the sufficient removal of un-reacted
chemicals and salt ions. The buffer solution was changed every 2-3h for a total of 3
times before leaving it dialysis overnight. At the end of the dialysis procedure, the
solution was retrieved from the dialysis pocket and kept in 4 ◦C until further analysis
or experiment.
4.2.3 The morphology of ChiNPs by Transmission Electron Microscopy
(TEM)
In order to confirm the synthesis of ChiNPs, the NPs were imaged with negative
staining TEM. One drop of chitosan nanoparticle dispersion was placed on a carbon
grid and allowed to settle for 2mins. Grid was swished through 2% uranyl acetate
stain droplet and excess solution was removed with a filter paper. All samples were
prepared in the method described above. Samples were imaged using a Philips CM-
100 TEM operated at 100kV, spot3, 200µm condenser aperture and 70µm objective
aperture. Images were captured using an SIA L3-C digital camera (Scientific Instru-
ments and Application, Duluth, GA). Magnification was varied based on the quality
of the results. Images were saved for further analysis.
4.2.4 The hydrodynamic size and zeta-potential measurements by zeta-
sizer
Hydrodynamic size and zeta-potential were measured using a zetasizer (Zetasizer
Nano ZS, Malvern Instruments Ltd, USA). The software affiliated to the instrument
generated size quality report, z-avg, intensity and polydispersity indices (PDIs), and
z-potential. The zeta-potentials were estimated from the electrophoretic mobility
measurements using the Smoluchowski model. To minimize the fluctuation caused by
temperature change and transfer samples, all samples were equilibrated 1-2h before
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each measurement at room temperature. 1ml NP suspension was loaded to the dis-
posable cuvette carefully to avoid bubble formation. Each measurement was repeated
at least three times. Data was saved for further analysis.
4.2.5 The effects of ionic strengths on the hydrodynamic size and zeta-
potential by zetasizer
Hydrodynamic size and zeta-potential were essential factors to evaluate stability
of ChiNPs in different salt concentrations. The measurements were conducted as
described in the above measurements. For higher ionic strength buffers (> 50mM
NaCl), only two measurements were conducted in zeta-potential test to minimize the
erosion of the cuvette. ChiNPs were incubated in different ionic strength buffers (0.01
XPBS-1 XPBS) at room temperature for 2 h or 24 h. Samples were loaded in cuvettes
for measurements. Data was saved for further analysis.
4.2.6 Materials
Chemicals were purchased from Sigma-Aldrich. Syringes were purchased from
Becton Dickison (BD) company. Cellulose Ester (CE) Dialysis membrane was pur-
chased from Spectra/Pro Biotech. Syringe filters were purchased from Pall Corpora-
tion (Life Sciences), GE healthcare (Life Sciences, Whatman), and Corning Inc.. The
freeze dryer (VirTis Benchtop K) is located at Center for Paralysis Research (CPR)
at Purdue University. The Zetasizer (Zetasizer Nano ZS, Malvern Instruments Ltd,
USA) is located in Birck Nanotechnology Center at Purdue University. The TEM is
located at Life Science Microscopy Facility at Purdue University.
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4.2.7 Statistics
All data were represented as means ±SD. Statistical analysis was conducted using
one-way ANOVA (SAS 9.2, SAS institute inc., NC, USA). Values were accepted as
being statistically significant difference if the P value was less than 0.05.
4.3 Results
4.3.1 Transmission Electron Microscopy (TEM)
The effect of pH on ChiNP formations
The morphologies of ChiNPs were observed by TEM negative staining technique.
As shown in Figure 4.2, MC-TPPNPs were formed in both pH 4.3 (Figure 4.2 A)
and pH 9.1 (Figure 4.2 B). ChiNPs appeared as dark spheres which were stained by
uranyl acetate. After 2 week’s air dried at room temperature, the global shape of
all NPs was still preserved (Figure 4.2C,D). No distinct difference of the morphology
and size distributions of Chi-TPPNPs was observed between two pH conditions.
MC-DSNPs were formed as dark spheres only in acidic pH(DS) environment (Fig-
ure 4.3 A). When the pH of DS solution increased from 4.6 to 6, only fiber-like
aggregation was formed (Figure 4.3 B).
The effect of volume ratios on the formation of MC-DSNPs
The morphologies of MC-DSNPs with different volume ratios: 5:3, 5:5, 5:8.5 are
shown in Figure 4.4. The edges of MC-DSNPs were found to be smoother when
the Chi/DS volume ratio was above 5:3 (Figure 4.4 A). Large NPs (size more than
200nm) were both found in volume ratio at 5:5 and 5:8.5 preparations (Figure 4.4
B-2 and C-2).
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Fig. 4.2. The morphologies of MC-TPPNPs by TEM. MC-TPPNPs
were synthesized when pH (TPP) was adjusted as 9.1 (A, C) or 4.3
(B, D). The MC-TPPNPs were successfully synthesized and appeared
as dark spheres due to stain with 2% uranyl acetate. The sizes were
accumulated in two ranges : around 50nm and 150nm. No obvious
difference of morphology or size was noticed between two pH condi-
tions of TPP. However, in 2 weeks, more MC-TPPNPs with lager size
were observed. (A) NPs -TPP (pH9.1) Day 1, (B) NPs -TPP (pH4.3)
Day 1, (C) NPs -TPP (pH9.1) Day 14, (D) NPs -TPP (pH4.3) Day
14. The scale bar equals 200nm.
The effect of purification methods on the morphology of ChiNPs
The morphology changes of MC-TPPNPs (pH 4.3) after dialysis, lyophilization,
and re-suspension in the PBS were recorded by TEM in Figure 4.5. After 24 h
dialysis, NPs and heterogeneous aggregations were co-existed (Figure 4.5 A). NPs
were identified as dark spheres in all figures. The large heterogeneous aggregations
were likely due to insufficient dialysis. Unreacted chitosan polymers were not dissolved
at neutral pH. NPs were filtered at 0.45 µm and then subjected to dialysis. In Figure
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Fig. 4.3. The morphology of MC-DSNPs and aggregations. The mor-
phology of MC-DSNPS synthesized at DS at pH 4.6 (A) and pH at
6 (B). MC-DSNPs were successfully formed as dark spheres in (A).
However, (B) only fiber-like aggregations were formed when DS pH
was increased to 6. The scale bar equals 200nm (A) and 0.5um (B).
4.5 B, much less aggregation was observed. After lyophilization (Figure 4.5 C), NPs
were preserved and no distinct morphology change was noticed. However, NPs tended
to aggregate after being re-suspended in PBS (Figure 4.5 D).
The morphology changes of MC-DSNPs (v/v, 5:8.5) after dialysis, lyophilization,
and re-suspension in the PBS were monitored in Figure 4.6. NPs were filtered at 1.2
µm and then subjected to dialysis for 24 hours. The morphology of NPs was preserved
in both dialysis and lyophilization. However, NPs tended to aggregate after being
re-suspended in PBS (Figure 4.6).
The effect of drug loading on the morphology of ChiNPs
Two types of drugs, DEX and HY were incorporated into MC-TPP and MC-
DSNP formations. All NPs appeared as dark spheres. Some of dark spheres had a
couple of tiny white defects (dots) close to the edges. Those tiny white defects were
likely air bubbles induced by vigorous stirring during the NPs formation, which was
in agreement with the fact that only electron dense materials were shown as dark
object in TEM. There was no distinct difference of morphology observed in Figure
4.7.
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Fig. 4.4. The morphology of MC-DSNPs prepared with different vol-
umes of DS. The MC-DSNPs were successfully formed in all prepara-
tions. The edges of NPs became smoother when the DS volume was
increased. (A) MC: DS-5: 3(v/v). (B-1, B-2) MC: DS- 5: 5(v/v).
(C-1, C-2) MC: DS- 5: 8.5(v/v). In MC/DS(5: 5, 5 : 8.5) larger sizes
were also observed(B-2, C-2). The scale bar equals 1um (A, B-2),
200nm (B-1, C-1), and 2um (C-2).
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Fig. 4.5. The morphology of MC-TPPNPs (pH4.3) subjected to
different purification methods. MC-TPPNPs (pH4.3) appeared as
dark spheres. During dialysis, some extra chitosan polymers were
insoluble in deionized water and appeared as cloudy aggregations
(A). After removing large aggregations by filters, the morphologies
of MC-TPPNPs were preserved in post-dialysis samples (B). The
lyophilization did not affect the morphology of the NPs (C). The
re-suspension of NPs in PBS caused some aggregations. (A) MC-
TPPNPs post-dialysis in deionized water. (B)MC-TPP filtered with
syringe filters and then subjected to dialysis in deionized water (C)
MC-TPPNPs post-freeze-drying and re-suspended in deionized water
(D) MC-TPPNPs post-freeze-drying and re-suspended in PBS. The
scale bar (A, D) 1µm, (B) 20nm, (C) 0.1µm.
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Fig. 4.6. The morphologies of MC-DSNPs after lyophilization. The
morphologies of MC-DSNPs subjected to lyophilization and resus-
pended in deionized water (A) and PBS (B) were preserved. But
some aggregation was observed in PBS suspensions (B). The scale
bar (A) equals 0.2µm, (B) equals 0.5µm.
Fig. 4.7. The morphologies of MCNPs loaded with drugs. No obvious
morphology changes of MCNPs were observed between pre-loading
and post-loading. (A) MC-TPPNPs pre-loading, (B) MC-TPP post-
loading with DEX 1mg. (C) MC-TPP post-loading with HY 1mg, (D)
MC-DS pre-loading, (E) MC-DS post-loading with DEX 1mg (F) MC-
DS post-loading with HY 1mg. Particles loaded with drugs appeared
darker than the pre-loading conditions. The scale bar equals 200nm.
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4.3.2 Size and zeta-potential results
Figure 4.8 showed a representative figure of size distribution by intensity data
obtained with the measurement of MC-TPPNPs where pH (TPP) was 4.3. Two major
size populations in MC-TPPNPs were indicated as two peaks in the intensity figure
which were 28.9 nm and 151.15 nm, separately. A similar bimodal size distribution
in the intensity profile was also observed in MC-TPPNPs where pH (TPP) was 9.1
(data not shown). The size of MC-TPPNPs were in the range of 100-200nm and
the zeta-potential was in the range of 20-35mV. As the pH (TPP) increased from
4.3 to 9.1, the sizes of NPs decreased from 38.91± 2.1nm to 24.17±10.9nm and from
151.15±7.707nm to 128.15±21.14nm. By increasing 30% the volume (TPP), the sizes
of NPs decreased 3%-15%. Both higher pH (TPP) and volume (TPP) suggested a
trend of tighter binding between Chi and TPP molecules. However, no significant
difference was observed among different preparations (Table 4.2, P>0.05).
Fig. 4.8. The representative size distribution of MC-TPPNPs by in-
tensity. A bimodal size distribution by intensity of MC-TPPNPs was
observed when NPs prepared at pH4.3 of TPP.
Chi-DSNPs were prepared with different volume ratios (5:3, 5:5, and 5:8.5). In
Figure 4.9, the average size of Chi-DSNPs was 217.76±12.97nm. Two size peaks were
detected and shown as intensity 1 and intensity 2. As the volume ratio decreased from
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Table 4.2
The size distribution and zeta-potential of MC-TPPNPs synthesized
in different pH conditions. The size of MC-TPPNPs were in the range
of 100-200 nm and the zeta-potential was in the range of 20-35 mV.
MC-TPPNPs were positively charged which indicated the free amine
groups of chitosan polymers spared on the surface of the NPs. No sta-
tistical significance was observed between different pH or v/v groups
(P>0.05). The trend of the size decreasing was noticed with increas-
ing TPP volumes and decreasing pH of TPP.
size pH 4.3 pH 9.1
MC/TPP (v/v) 5:2 5:1.5 5:2 5:1.5
intensity1 (nm) 147.43±22.45 151.15±7.707 119.5±11.74 128.15±21.14
intensity2 (nm) 32.94±8.35 38.91±2.1 26.82±7.12 24.17±10.9
z-p (mV) 27.7±5.52 31.13±9.26 30.91±3.68 28.81±4.059
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5:3 to 5:5 and 5:8.5, the size (intensity 1) decreased significantly from 274.8±16.83
nm to 227.6±26.86nm (5:5) and 218.9±26.51nm (5:8.5) (P<0.05). No significant
difference was found in intensity2 (P>0.05). Zeta-potentials of MC-DSNPs were
significantly decreased as DS volume increased (P<0.05). The polarity was switched
from positive to negative when the volume ratio was lower than 5:5.
Fig. 4.9. The hydrodynamic sizes and z-potentials of MC-DSNPs
synthesized with different volume ratios. MC-DSNPs had a bimodal
size distribution which was represented as intensity 1 (around 200 nm-
300 nm) and intensity 2 (40-60 nm). As volume ratio increased from
5:3 to 5:5 or 5:8.5, the size decreased significantly which were shown
in intensity1 (P<0.05). Z-avg described the overall average size of
NPs. All MC-DSNPs were around 210 nm (Z-avg). Zeta-potential
was switched significantly from positive to negative as the volume of
DS increasing from 3 ml to 5 ml or 8.5 ml (P<0.05). All data was
represented as mean ± SD.
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The effect of ionic strength on the size and zeta-potential of MCNPs
In Figure 4.10, MC5-TPP2NPs were diluted with different ionic strengths buffers:
0-1 XPBS at room temperature for 24h. No obvious difference in the hydrodynamic
size was observed in NPs buffered with low ionic strengths between 0-0.1X PBS
(P>0.05). In higher ionic strength buffers (0.3-1 XPBS), the size of NPs increased 5
times (P<0.05) which indicated that large aggregations were induced. The larger SDs
of NPs in stronger ionic strengths (0.3 X-1X PBS) indicated that NPs were in-stable
and therefore variable sizes were detected. The significant less cationic charge of NPs
in higher ionic strength (less than 0.03 XPBS) was observed, which indicated the
neutralizing effects produced by polarized salt ions on the surface of NPs (P<0.05).
In Figure 4.11, MC-DSNPs (v/v: 5/5) were diluted with different ionic strengths
buffers: deionized water, 0.1 XPBS, 0.5 XPBS, and 1 XPBS at room temperature for
2 h and 24 h. No obvious difference in the hydrodynamic size was observed in NPs
buffered with different ionic strengths (P>0.05). But the SDs in high ionic strengths
(0.5 X and 1 XPBS) were much higher than the lower ones (0 and 0.1 XPBS), which
indicated that the aggregation of NPs might be formed and precipitations might be
anticipated. Indeed, the concentrated MC-DSNPs samples showed obvious precipita-
tion quickly after diluting gently with concentrated salt ions (data not shown). The
zeta-potential (post-24h) was significantly more negative after dialysis, indicating the
removal of unreacted positively charged chitosan polymer in the suspension via dial-
ysis. Significantly less anionic NPs in higher ionic strength (0.5 XPBS and 1X PBS)
were observed, which indicated the neutralizing effects produced by polarized salt
ions on the surface of NPs (P<0.05).
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Fig. 4.10. The hydrodynamic sizes and zeta-potentials of MC-
TPPNPs buffered with different ionic strengths. No obvious differ-
ence in the hydrodynamic size was observed in NPs buffered with
low ionic strengths (less than 0.3 XPBS) (P>0.05). In high ionic
strengths (0.3-1 XPBS), the size increased significantly, prepared in
both pH conditions (P<0.05). The zeta-potential of NPs decreased
significantly as the ionic strength increased (0.03 XPBS-1 XPBS), in-
dicating the neutralizing effects produced by polarized salt ions on
the surface of NPs. All data was compared with the results obtained
in deionized water. N=3. The data was represented as mean ± SD.
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Fig. 4.11. The hydrodynamic sizes and zeta-potentials of MC5-
DS5NPs buffered with different ionic strengths. MC-DSNPs
(v/v: 5/5) were subjected to different ionic strengths buffers (deion-
ized water, 0.1 XPBS, 0.5 XPBS, and 1 XPBS). No obvious difference
in the hydrodynamic size was observed in NPs buffered with differ-
ent ionic strengths (P>0.05). But the SDs in high ionic strengths
(0.5 X and 1 XPBS) appeared much higher than the lower ones (0,
0.1 XPBS) indicated that the aggregation of NPs might be formed
and precipitations might be anticipated. The zeta-potential (post-
24h) increased significantly after dialysis, indicating the removal of
extra positive charged chitosan polymer in the suspension via dialy-
sis. The significant decrease of zeta-potential in higher ionic strength
(0.5 XPBS and 1 XPBS) was observed (P<0.05) and indicated the
neutralizing effects produced by polarized salt ions on the surface of
NPs. Size values were compared with the results in deionized H2O.
Potential values were compared with results in the pre-dialysis condi-
tion. N=3. The data was represented as mean±SD.
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4.4 Discussion
4.4.1 The impact of pH value
In this work, two types of ChiNPs were synthesized, Chi-TPPNPs and Chi-DSNPs.
Based on the ionic gelation method, the protonated chitosan polymer acted as a
backbone, providing binding sites for anionic molecules (DS/TPP) [127, 128]. With
a pKa value of 6.5, chitosan can be protonated at the free amino groups which is
dependent on the DA of chitosan and the pH value of the buffer. The base titration
curve describes the change of pH as a function of the volume of bases, usually with
sodium hydroxide (NaOH) added. The base titration curve of chitosan solution with
2 M NaOH added drop-wise, showed a sharp increase of pH value both at the range
of pH less than 4 and higher than 6. However, at the range of pH (4 to 6), the
rate of the pH increased much slower as NaOH was added (data not shown). When
the pH was less than 4, there were many free protons provided by acetic acid in the
chitosan solution that reacted with the hydroxyl groups in NaOH and this resulted in a
higher pH value of the solution. When all free protons were interacting with hydroxyl
groups, adding more NaOH led to the competition of binding with protons between
the hydroxyl groups and the amino groups of chitosan. Therefore, it was observed as
a slow increasing of pH at the range between 4 and 6. When the pH was greater than
6, almost all chitosan polymers might be deprotonated. Adding more NaOH meant
the net increase of the number of hydroxyl groups. Then, the sharp increase of pH
was observed again. In high pH environment, chitosan became less soluble and the
solution appeared cloudy which indicated polymer aggregation and precipitation. It
was also observed in Shu and Zhu’s study where chitosan (DA14% and MW 400KDa)
was suggested to be completely protonated at pH 4.7 and deprotonated at pH 8 [129,
130]. Therefore, to ensure the solubility of chitosan, with sufficient repulsion between
protonated chitosan polymers and minimization of the number of free protons, the
pH was adjusted between 4-5. A large number of free protons in the solution can
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weaken the electrostatic interactions between chitosan polymers and TPP or DS and
prevent the formation of the NPs.
The formation of Chi-TPPNPs was suggested to be independent of the pH value
of TPP (Figure 4.2), which, however, was not applicable for the formation of Chi-
DSNPs. The NP formation was largely influenced by the pH of the mix solution, which
needs to be monitored and controlled at the range of 4-5 to ensure the solubility of
chitosan, mainly because both TPP and DS were in the forms of sodium salt and they
were water-soluble. When the pH of the mix was higher than 5, the effects of the
intra-/inter-molecular attractions of chitosan polymer became dominant due to the
decreased degree of protonation of chitosan. Therefore, it often resulted in a fiber-like
aggregation (Figure 4.3 B) or the aggregation of microparticles [131]. The primary
attraction forces were H-bonding and hydrophobic interactions between acetyl chains
of chitosan.
In our work, the increase of the volume of TPP did not result in a significant
difference (decrease) of the size of MC-TPPNPs, due to the choice of the volume/ratio
selected (Table 4.2). Fan reported a TPP mass-dependent effect on NP size [127].
When more TPP was available to bind with higher amount of amino groups in the
solution, the density of cross-linking increased; therefore, the size of single NP was
expected to decrease. However, extra TPP can also bridge adjacent small NPs or
chitosan polymers together forming large aggregations. Moreover, the protonation of
TPP is pH dependent as well. The reduction of the protonation of TPP in high pH
resulted in a higher concentration of tripolyphosphate ions [132]. In other words, the
higher charge density of TPP at pH of 9 can result in a larger number of binding sites
with chitosan polymer when compared with TPP at pH of 4. However, the solution
with higher pH also enhanced the competition effect between tripolyphosphate ions
and hydroxide ions interacting with protonated chitosan polymers [133]. A significant
change induced by pH (TPP) on the sizes and zeta-potentials was not observed in
out study.
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4.4.2 The impact of MW
The impact of different MWs of anionic molecules on both the size and zeta-
potential of NPs were investigated (Table 4.2 and Figure 4.9). TPP with a lower MW
(<400Da) and smaller charge density compared to DS, behaving as an anionic bead,
was bound with multiple cationic amino groups either from single or several chitosan
polymers due to the poly-anionic ions (polyphosphate ion) in TPP. Therefore, the
size and zeta-potential of Chi-TPPNPs were largely dependent on the properties of
chitosan. The positive zeta-potential of Chi-TPPNPs was contributed by the free
amino groups of long chitosan polymer extending towards the surface of the NPs. On
the other hand, DS with an average MW 20 times of the MW of TPP, exhibited a
higher modification effect on the properties of NPs which was tailored by the volume
ratio of Chi /DS.
4.4.3 The impact of volume ratio
The switch of the polarity of the zeta-potentials of Chi-DSNPs was observed when
the volume ratio of Chi/DS was less than 5:3, indicating the dominant charge effect
produced by the higher volume of DS (5:5 and 5:8). The size of Chi-DSNPs also
decreased significantly as the DS volume was increased [134]. Continue decreasing
Chi/DS volume ratio from 5:5 to 5:8 did not lead to a significant change of sizes
and zeta-potentials of NPs. These results suggest that the cationic amino groups of
chitosan polymer were saturated by binding with sulfate groups of DS at the volume
ratio of 5:5.
4.4.4 The impact of freeze-drying
Freeze-drying, also known as lyophilization, is a common method to dry and
preserve chemicals in industrial applications [135]. A freeze-drying cycle is divided
into three steps: freezing, primary drying and secondary drying. The removal of
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water from NPs can increase the stability and storage time [136]. However, dur-
ing the process of freeze-drying, NPs might be challenged with various stresses from
the extremely low temperature, vacuum, and ice crystals. The most common cry-
oprotectants for lyophilization of NPs are sugar based, such as glucose, sucrose, tre-
halose, and lactose. Trehalose was suggested as a good candidate of cryoprotectant
for biomolecules [137]. It serves as a protective layer to substitute water molecules
by forming H-bonds with polar groups of the NPs. It is also possible to freeze-dry
NPs without the pre-treatment of cryoprotectant, such as poly(ǫ-caprolactone) NPs.
Our results (Figure 4.5 C and Figure 4.6 A) showed that the overall shape of NPs
was preserved after lyophilization. However, the solubility of NPs after lyophilization
was limited, both observed in de-ionized water and PBS, which indicated enhanced
inter-/ intramolecular interactions between NPs after freeze-drying (Figure 4.5D and
Figure 4.6B). 5% trehalose was used in the freeze-drying of ChiNPs [138].
4.4.5 The impact of drug loading
Our TEM results showed that no obvious morphology and size changes were ob-
served between pre- and post-drug loadings (Figure 4.7). The drug molecules were at-
tached on the ChiNPs via electrostatic interactions. Since the MWs of drug molecules
were low (Hy: 160Da and Dex: 400Da), the drug loading might not generate signif-
icant impacts on the size of NPs, if the added drug volume is low. However other
studies indicated that both zeta-potential and size of NPs were modified by drug
loading [27, 134]. ChiNPs were also tested to load genes, peptides, protein drugs,
anticancer chemical drugs, and other drugs [121].
4.4.6 The impact of ionic strength
The colloidal homogenous suspension of NPs is maintained by the opposite effects
of diffusion/convection and gravitational forces [135]. The concentration gradient is
the driving force for the movement of particles from a region of high concentration to a
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region of low concentration. During these diffusion processes, particles randomly col-
lide with other molecules in the suspending medium due to the spontaneous thermal
motion, referred to as Brownian motion. The collision elevates the chance of mutual
interactions between particles and molecules. Gravitational forces counteract with
the diffusion force by pulling down the large aggregation of particles and inducing
precipitations. Both Brownian motion and gravitational forces are size-dependent.
When the particle size is within nano- or micro-size, Brownian motion dominates and
maintains the stability of the suspension. However, when counter-ions are introduced
into the suspension, the adsorption of counter-ions on the surface of NPs might sup-
press the ionic repulsion between NPs, causing particle aggregation/agglomeration.
The large size of NPs can further enhance the effect of gravitational forces and lead
to particle precipitation.
In our work, ChiNP was more stable in the low ionic strength environment where
enough ionic repulsions were established by charges of NPs (zeta-potentials were
greater than ±25mV, Figure 4.10 and Figure 4.11). After the ionic strength increased
(50mM and 150mM PBS), the hydrodynamic size of Chi-TPPNPs significantly in-
creased accordingly (prepared in both pH conditions). These observations were also
suggested in Lopez’s work [139]. The increase of the sizes and the decrease of the
zeta-potentials of Chi-TPPNPs were indicated to be induced by an accumulation of
counter-ions on the hydrated layer of the NPs via electrostatic interactions, when
NPs were incubated with high ionic strength buffers [127]. The accumulation of
counter-ions on the NPs neutralized the charge of the NPs which was observed as the
zeta-potential decreased. A reduction of zeta-potential of NPs indicated less repulsion
forces between particles which in turn led to a greater chance of the aggregation of
individual small particles. As a result, the size of NPs increased which was shown
in the data of Chi-TPPNPs. Similar results were observed in the reduction of the
zeta-potential (after 24h incubation) of Chi-DSNPs (Figure 4.11). However, no such
trend was observed in the size measurement of Chi-DSNPs. The difference of the
impact of the ionic strength on the size between Chi-TPPNPs and Chi-DSNPs might
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be associated with the MWs of TPP (387Da) and DS (10KDa), which differ by ap-
proximately 2 orders of magnitude. The higher MW of DS indicated longer chain
length, higher anionic charge density, and stronger binding forces with chitosan poly-
mers, compared with TPP. Nevertheless, the storage of ChiNPs in low ionic strength
buffer is suggested to maintain the stability of the NPs suspension in the long term.
Chitosan derivatives and PEG-coating were used to improve the performance of NPs
by increasing the charge density and the surface roughness which enhances the steric
hindrance between NPs [84,117,140,141].
Other factors were also found to influence the formation of NPs, such as: the con-
centration of acetic acid, the temperature, the stirring speed [127], the ionic strength
during synthesis [142], MW and DA of chitosan [140,143].
4.5 Conclusion
In conclusion, our work investigated the ionic interactions between chitosan poly-
mer with two types of anionic molecules, namely TPP and DS. Chi-NPs were success-
fully synthesized as sphere NPs. Major factors that affect the properties of ChiNPs
were investigated, such as pHs, MWs, volume ratios, purification methods and ionic
strengths. In agreement with other studies, the sizes and zeta-potentials of ChiNPs
was well preserved if stored in the low ionic strength buffer. Higher ionic strength
changed the properties of ChiNPs significantly. However, the size of Chi-DSNPs was
less affected. Therefore, we chose Chi-DSNP as the candidate for further in vitro and
in vivo studies.
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5. THE NEUROPROTECTION BY CHITOSAN
NANOPARTICLES (CHI-NPS) - AN IN VITRO AND AN
IN VIVO STUDIES
The most important factor associated with a promising medical innovation is if it is
performed as expected. There are two general models to test functionality (discussed
here as ChiNPs): in vitro and in vivo evaluations. Each of these provides complemen-
tary information to each other. For example: (1). An in vitro test can reveal if the
therapy has a significant effect on a model cell system. It can give the insights into the
mechanism of the action the therapy. However, it does not provide any information
regarding the usefulness of the therapy on an animal or a human being. (2). An in
vivo study is performed to reveal the effect of a therapy in an animal or a human
being. It can provide the knowledge related with behavior recovery, dose adjustment,
and side effects which are the key information required for the application of clinical
studies. However, it does not provide understanding of the mechanism of the action.
Therefore, a proper evaluation of a promising therapy should be performed at both
levels of investigations in vitro and in vivo.
In this chapter, we first explored if the neuroprotective effects of ChiNPs can inter-
fere with secondary injury mechanism. We used a specific toxin (hydrogen peroxide)
for a specific immortal cell line (BV-2). The beneficial effects of ChiNPs were also
tested in a spinal cord injury model. We used a crush/compression model of injury
to the mid-thoracid spinal cord of an adult guinea pig. The particular assay we em-
phasized was the conduction of nerve impulses, lost after the injury, but hopefully
recovered after the experimental therapy.
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5.1 Introduction
A spinal cord functions as an informational highway to transmit and coordi-
nate both motor and sensory information that is coded via electrical signals in the
body. Spinal cord injury (SCI) destroys the passage of the information by mechani-
cally/biochemically damaging the spinal cord tissue [1, 144].
Oxidative stress plays a critical role in many diseases and trauma such as sec-
ondary injury in SCI, inflammation, immune-based disease (arthritis, infections) and
neurodegenerative disease (Parkinson’s Syndrome, Multiple Sclerosis, MS) [10, 21,
23, 145–150]. Oxidative stress describes the imbalance between the potential dam-
age caused by the generation of reactive oxygen species (ROS) and the capability of
ROS deactivation by scavengers produced by a biological system. ROS is a collec-
tive term that includes oxygen radicals (superoxide anion O·−2 and hydroxyl radicals,
·OH) and some non-radicals, such as H2O2. Free radicals are highly toxic due to ac-
tive unpaired electron, which can damage many biological molecules, including lipids,
proteins, and/or nucleic acids [151]. For instance, the unpaired electron of a free
radical can remove electrons from the carbon-carbon double bonds on cell membrane
lipids, leading to the initiation of lipid peroxidation (LPO) [152,153].
As one of the major events in free radical mediated cell injury, LPO can occur
in multiple sites simultaneously which results in fatty acid oxidation, lipid cross-
linking and/or breakage of covalent links between a membrane glycoprotein and its
membrane lipids. Consequently, the transient formation of polarized phospholipid
peroxides might create hydrophilic micro-centers due to the higher polarity of per-
oxides than phospholipids. Therefore, these hydrophilic micro-zones may result in
increased membrane permeability [20, 154, 155]. LPO can also produce more radi-
cals or other toxins (aldehydes) as by-products and facilitate positive feed-back, or
self-reinforcing, LPO loops. Such aldehydes include the endogenous occurring 4-
Hydroxynonenal and acrolein which have been implicated in membrane damage and
secondary injury [18,156,157].
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Further, the non-regulated generation of H2O2 is a well-known source of oxidative
stress. H2O2 is the intermediate product in the conversion of O
·−
2 into H2O in the
electron transport chain during oxidative phosphorylation in the cell mitochondria.
Any disruption of this equilibrium (such as a mechanical stress) can cause activated
oxygen by-products (O·−2 and H2O2) to overwhelm antioxidant enzymes. H2O2 can be
further converted into ·OH, in the presence of iron (Fe2+) or other heavy metal ions.
·OH is highly reactive and capable of attacking nearby molecules within nanosec-
onds [158]. Several studies have documented that high concentration of H2O2 results
in the disruption of membrane integrity and apoptosis [159–161]. Unfortunately, there
is no known direct scavenger to inactivate ·OH due to its extreme reactivity. However,
cells are equipped with an inherent anti-oxidant defense system to monitor/scavenge
the parent compounds, O·−2 and H2O2, as well as other ROSs during the normal
oxidative phosphorylation process [162]. This native anti-oxidant defense system in-
clude enzymes such as superoxide dismutase (SOD), catalase, glutathione peroxidase
(GSHPx) as well as, vitamin E, and glutathione [163]. However, during secondary
injury of SCI, the initial damage triggers a production of ROS which quickly depletes
the cellular anti-oxidation capability and leaves cells ( in our discussion - neural cells)
particularly vulnerable to oxidative stress [148,164]. Exogenous antioxidants (reduc-
ing agents) work as direct ROS scavengers and inhibit or prevent oxidative damage
induced by ROS. They are often thiols, ascorbic acid, or polyphenols, obtained from
a balanced diet or drugs.
Chitin is a natural cationic polysaccharide and can be derived naturally or chem-
ically from certain fungi, insect and crustacean shells. Its derivative, Chitosan, is
composed of N-acetyl-glucosamine and glucosamine subunits. Chitosan has been
widely used as a biomaterial in food processing, tissue engineering, and in the phar-
maceutical industry due to its biodegradability and biocompatibility. The primary
amino groups on the glucosamine units of a chitosan polymer partially contribute to
various biological activities, such as anti-tumor, antimicrobial, anti-ROS, hemostasis,
and as a membrane fusion agent [50–53,161,165]. The ability of chitosan to suppress
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the production of nitric oxide or ROS stress was reported in murine microglia cell,
human umbilical vein endothelial cells, and murine melanoma cells [153, 161, 166].
Chitosan was also suggested to inhibit the production of ROS and LPO by restor-
ing the integrity of membrane lipids following the compression injury in isolated
spinal cord segments [26]. Recently, chitosan was also used as a nanomaterial to
encapsulate and deliver therapeutic drugs and imaging agents in various biological
systems [27, 122, 123, 129, 167, 168]. The advantages of chitosan nanoparticles versus
chitosan or other synthetic polymer-based nanomaterials are its inherent bioavailabil-
ity, biodegradability, biocompatibility, enhanced solubility, reduced hemostasis, and
accessibility for modification - such as drug loading and surface modifications.
Our previous work found a dual effect of neuroprotection by both bare chitosan
nanoparticles and drug-doped (toxin scavengers) nanoparticles in an acrolein-induced
PC12 cell death model. The inhibition of endogenous enzyme leakage and the preser-
vation of viable cells by chitosan nanoparticles were suggested through the restoration
of compromised membrane integrity [27].
In this work, we further investigated neuroprotection by chitosan nanoparticles
on BV-2 rat microglia challenged by H2O2 exposure. This cell injury model is closely
associated with the oxidative damage in secondary injury in SCI. The reduction of
cell viability and cell proliferation was observed in a time and dose dependent manner
after exposure with H2O2 at different concentrations . We screened the“rescue” effects
of Chitosan-Dextran Sulfate nanoparticles (Chi-DSNPs) without a drug cargo on a
H2O2 induce BV-2 cell damage at different administration time points and incubation
periods. We also investigated the mechanisms of H2O2 induced cell death to give new
insights on the neuroprotective effects generated by Chi-DSNPs.
We are also interested in the beneficial effects derived from ChiNPs on SCI models
in whole animal studies. Experimentally induced standardized compression SCI was
performed on sedated guinea pigs. We conducted somatosensory evoked potentials
(SSEP) measurements on animals at pre- and post-compression injury conditions.
SSEP provided the function of the signal conduction through sensory pathways of
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spinal cord. SSEP on the lightly sedated animals after the treatment of ChiNPs was
monitored at Day 1, week 1 and week 2.
5.2 Methods and materials
5.2.1 BV-2 cell culture
BV-2 cells are an immortalized mouse microglial cell line that exhibits the mor-
phological and functional characteristics of microglia. The cells were maintained in
D1152-Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 0.044M
sodium bicarbonate, 10% fetal bovine serum (FBS) and 100U/ml penicillin and
100ug/ml streptomycin (Sigma, A5955). The cells were cultured in a 5%CO2 and
95% air incubator in a humidified cell incubator at 37◦C. 0.25×105 Cells were seeded
in a 75cm2 flask. The sub-culture was conducted when 80% confluency was reached,
on average, after 3days of cell culture. Culture medium was changed every other day.
5.2.2 Chi-DSNPs and H2O2 treatments
For viability measurements, H2O2, BV-2 cells were seeded at a density of 1.5E5/well
in a 12-well plate overnight. The next day, the medium was replaced with freshly pre-
pared H2O2 solutions in culture medium without serum at concentrations of 0, 11, 55,
110µM and cells were cultured for 1h-4h. For viability measurements in response to
Chi-DSNPs with the challenge of H2O2, the concentration of 5.5µMH2O2 was chosen
to induce BV-2 cell death for testing the neuroprotective effect of Chi-DSNPs. BV-2
cells were seeded at a density of 0.5E5/well in a 24-well plate overnight. Freshly pre-
pared 1mg/ml, 10ul NPs was administrated at 0 and post-15mins after the addition of
H2O2. Cell viability was measured at the end of a 2h incubation using a trypan blue
exclusion test. For proliferation measurements in response to Chi-DSNPs, BV-2 cells
were seeded at a density of 1E4/well in a 96-well plate overnight to achieve cell attach-
ment to the bottom of the well. Cell medium with serum was replaced with diluted
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NP suspension at a concentration of 0, 0.1,0.2, 0.5mg/ml, 100µl. For proliferation
measurements in response to H2O2, cell medium with serum was replaced with H2O2
at 0, 0.05, 0.1, 0.2, and 0.3mM for 20h. For proliferation measurements in response to
Chi-DSNPs with the challenge of H2O2, cells were pre-treated with 0.2mg/ml, 100µl
Chi-DSNPs for 4h before incubating with 0.05mM H2O2. In these experiments, cell
proliferation was measured using a WST-assay. The detail information of WST assay
can be found in the following.
5.2.3 Trypan blue dye exclusion test
Medium was carefully removed and cells were gently rinsed once with warm 1X
PBS. Cells were incubated with 0.2% trypan blue, diluted with 1X PBS, for 2mins.
Then, trypan blue solution was removed and replaced with 1X PBS. Necrotic cells
were stained with trypan blue and appeared as dark spheres. Viable cells were not
stained and appeared as bright spheres.
5.2.4 WST-1 cell proliferation assay
Cell proliferation was tested with a WST assay (Cayman). The assay is based on
the conversion of WST-1 reagent into formazan salts by cellular mitochondrial enzyme
dehydrogenases in viable cells. The absorption was measured by a microplate reader.
10% (v/v) WST-1 agent was added to each sample well and a background control
well (no cells present, only cell medium). After 2h incubation at 37◦C in the dark,
the absorption of each well was measured in a multi-well plate reader at 450nm. The
final data was calculated by subtracting the background signal from the absorption
of sample wells. Four experiments were conducted, quadruplicate for each treatment.
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5.2.5 Phase contrast imaging
BV-2 cells were allowed to reach confluency in the 75cm2 flask. Then, cells were
harvested and seeded at 1E5/well in a 12-well plate. After overnight incubation, cells
attached well on the bottom of the well. Medium was replaced with H2O2 at 0, 0.05,
0.1, and 5.5mM. Cells were placed in a temperature and humidity controlled culture
chamber was connected to an Olympus IX81 Microscope System. Phase contrast
images were taken at a time interval of 30mins for 20h. Sequential images were taken
at fixed positions enabled by the multi-dimentional acquisition (MDA) program of
the microscope’s software.
5.2.6 Annexin V-FITC apoptosis detection
Early apoptotic cell death was detected by annexin V-FITC apoptosis probe (Ab-
cam). After the initiation of cell apoptosis, membrane phosphatidylserine (PS) is
translocated to the surface of the cell membrane from the inner surface of the plasma
membrane. The binding between PS and its high affinity protein annexin V will
stain the apoptotic cells with a convenyional FITC green fluorescent probe which is
pre-conjugated with the annexin V protein. Cells that have lost membrane integrity
will show red staining with propidium iodine (PI) throughout the nucleus and a halo
of green staining (FITC) on the cell plasma membrane surface.
BV-2 cells were allowed to reach confluency in the 75cm2 flask. Then, cells were
harvested and seeded at 1E5/well in 12well plates. Cells were exposed to H2O2 at 0,
0.05, 0.1, and 5.5mM to induce cell death. The adherent cells were trypsined gently
and washed once with 500ul of 1X binding buffer. Cells were incubated with 5ul
Annexin V-FITC and 5ul (50mg/ml) of PI for 5mins in the dark at room temperature.
Cells were centrifuged gently and re-suspend in 200ul 1X binding buffer. 100ul cell
suspensions were placed on a glass slide and mounted with a coverslip. Images were
taken by a (Nickon Diaphot 300 Microscope) at the incubation time of 0h and 4h for
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H2O2 (5.5mM) and 0h and 20h for H2O2 (0, 0.1, 0.05mM) with a dual filter set for
FITC and PI.
5.2.7 Compression injury in vivo
All animals used in this study were handled in accordance with, and prior ap-
proval by, the Purdue University Animal Care and Use Committee (PACUC). In this
study, every effort was made to reduce the number and suffering of the animals used.
The compression injury procedure can be found in the manuscript of Borgens 2002.
Adult female guinea pigs (Hartley strain) weighted in a range of 300 to 400mgs were
anesthetized with a intramuscular injection of Ketamine 60mg/kg, followed by xy-
lazine 10mg/kg. An adequate anesthesia throughout the procedure was confirmed
by a lack of response from a toe-pinch test. The aseptic surgery procedure was per-
formed. Briefly, the dorsal aspect of the anesthetized guinea pigs was shaved by an
electric clipper. Betadine and 70% alcohol were applied and wiped off at shaved ar-
eas subsequently. After identify the approximate area at T13 level, a one-segment
laminectomy procedure was performed to expose the spinal cord under a stereoscope.
The 15s-compression injury was induced by using a pair of modified forceps possess-
ing a spacer of 0.8mm. The previous experiments demonstrated that the compression
induced as described above can generate a complete block of SSEP conduction. The
muscle around the laminectomy was stitched together with a 3-0 prolene suture. The
skin was closed with Michel wound clips 7.5mm each. A 3ml of sterile lactated ringers
and carproten was injected subcutaneously to the animals. Then, animals were kept
warm by placing under a heat lamp until fully recovered and moved to Purdue Animal
Housing Facility where they received daily care.
5.2.8 ChiNPs treatment
The synthesis of ChiNPs can be referred to Chapter 4. ChiNPs were freshly pre-
pared prior to each experiment. 1mg/ml particles were mixed well in sterile lactated
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ringer solution and subcutaneously injected at the nape of the neck of the animals
30mins after the compression injury. The control groups were administrated with
1mg/ml silica NPs subcutaneously as well.
5.2.9 Somatosensory Evoked Potential (SSEP) recording
The measurements of SSEP on lightly sedated guinea pigs were used to evalu-
ate the function recovery of evoked potential conduction pre- and post- spinal cord
compression injury with the single administration of ChiNP suspension. The SSEP
recording procedure can be found in the manuscripts of Borgens [24,25]. The presence
or absence of SSEP through the lesion was used as the criteria to study the perfor-
mance of therapeutic effect of ChiNPs. Guinea pigs were intramuscular injected with
a mixture of ketamine 20mg/kg and xylazine 4mg/kg. Needle electrodes were placed
subcutaneously on the lightly sedated guinea pigs [49]. A first pair of stimulating pin
electrodes was inserted in the left hind-leg near the tibial nerve. A second pair of
stimulating electrodes was inserted in the ipsilateral foreleg near the medial nerve and
the abdomen. A pair of recording electrodes were inserted at the right side and the
front of the head, slightly left to the right eye. Two neural circuits were established.
The first one was the test circuit. Stimulation was conducted through the lesion,
from the tibial nerve to the contralateral side of the sensory cortex. The second one
was the control circuit. Stimulation was by-pass the lesion, from the medial nerve to
the contralateral side of the cortex. A switch box was designed to switch the stimu-
lating signal between tibial nerve and medial nerve without replacing electrodes. A
Nihon Kohden Neuropack 2 Stimulator/Recorder was used to generate the stimula-
tion and receive the evoked potential signals. The stimulation frequency was 200
HZ. The magnitude of the stimulation signal was adjusted until the twitching move-
ment surrounding the stimulation electrodes almost invisible. A complete blockage of
evoked potentials in the test circuit indicated a successful compression injury on the
spinal cord. A recovery of evoked potentials through the compression lesion on the
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spinal cord, recorded at the contralateral sensory cortex, from the stimulation of the
hind-legs, was suggested as a function recovery of electrophysiological conduction in
spinal cord injured animals. Evoked potentials were measured on the normal, post-
injury, Day1, Week1, and Week2 after stimulated at the tibial and median nerves
respectively. The evoked potential was recorded as a average waveform of three mea-
surements. Each measurement was generated by averaging 120 recordings.
5.2.10 Materials
WST-1 assay was purchased from Cayman Chemical company. Annexin V-FITC
apoptosis detection Kits was purchased from Abcam. BV-2 cells were a gift from Wen
Gao, Center for Paralysis Research (CPR). Adult female guinea pigs were purchased
from Hilltop and housed at Purdue animal holding facility. Ketamine and xylazine
were purchase from Purdue Veterinary School Pharmacy. Nihon Kohden Neuropack
2 Stimulator/Recorder (SSEP recorder) is located at CPR. Olympus IX81 and Nikon
Diaphot 300 Microscope is located at Doyle Laboratory at Purdue University. Other
chemicals and agents were purchased from Sigma-Aldrich.
5.2.11 Statistics
All data points were represented as means±standard deviation. Statistical analy-
sis was conducted using one-way ANOVA for comparison among more than 2 groups,
Tukey-Kramer Multiple Comparisons test for comparison between experiment groups
and Fisher’s exact test for in vivo evaluations (InStat software). Other values were
accepted as being statistically significant if the P value was less than 0.05.
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5.3 Results
5.3.1 Time and dose dependent cell death induced by H2O2
We first assessed the cell viability of BV-2 cells with 1h incubation of H2O2 at
different concentrations (0, 11, 55, 110µM). As shown in Figure 5.2, H2O2 greater
than 55µM induced more than 90% cell death within the 1st hour. Furthermore,
BV-2 cell death with 11µM H2O2 was monitored within a window of 0-4h.
5.3.2 Time and dose dependent inhibition of cell proliferation induced by
H2O2
H2O2 induced an inhibition of BV-2 cell proliferation within a window of 20h
measured with the WST-1 assay (Figure 5.3). Expansion of a viable cell population
always results in an increase in the activity of the mitochondrial enzyme dehydro-
genases, which as a consequence , leads to an increase of the signal intensity. As
expected, cell proliferation was suppressed as the concentration of H2O2 increased.
When the concentration of H2O2 was more than 0.2mM, no further decrease of cell
proliferation was detected with WST assay.
5.3.3 The effect of Chi-DSNPs on cell proliferation
As discussed above the effect of Chi-DSNPs on BV-2 cell proliferation was mea-
sured with WST-1 assay (Table 2). It was observed that cell proliferation within 20h
was not affected significantly by Chi-DSNPS up to 0.5mg/ml (P>0.05). There was
a mild trend for a reduction in cell proliferation, indicating a potential stress caused
by high concentrations of Chi-DSNPs on cell functions. As Chi-DSNPs concentration
was increased to 1mg/ml, cells were more susceptible to H2O2 challenge (data not
shown) which further confirmed our hypothesis of stress induced by NPs.
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Table 5.1
The effect of Chi-DS NPs on cell proliferation. Cell proliferation was
not affected by the incubation of Chi-DSNPs for 20hs at different
concentrations (0, 0.1, 0.2, 0.5mg/ml). A trend of reduction of cell
proliferation was noticed as the concentration of Chi-DSNPs was in-
creasing. However, no significant difference was observed between
different treatments (P>0.05).
Chi-DSNPs(mg/ml) 0.5 0.2 0.1 Medium (0)
Cell Proliferation
(Arbitrary Unit) 1.873±0.26 1.97±0.32 1.995±0.27 2.073±0.33
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Fig. 5.1. BV-2 cell viability challenged by H2O2. Dose and time
dependent cell death were observed when BV-2 cells incubated with
different concentrations and periods of H2O2. Viable cells were shown
with various morphologies and white halos. Non-viable cells were ap-
peared as dark spheres after treated with Tyrpan Blue. (A) Time
dependent cell death of BV-2 cells incubated 1h with 0, 11, 55,
110µMH2O2. (B) Dose dependent cell death of BV-2 cells incubated
11µMH2O2 for 0-4h. (C) The quantitative data of time dependent cell
death. (D) The quantitative data of dose dependent cell death. All
data was normalized and compared with control groups. Data was
represented as mean±S.D. **P<0.05, ***P<0.01.
5.3.4 The effect of Chi-DSNPs on cell viability challenged by H2O2
Enhancement of BV-2 cell viability by the administration of Chi-DSNPs at 0min
and 15mins after incubation with 5.5mM H2O2 was measured by the trypan blue
dye exclusion test. Results (Figure 5.4) showed that a 2.5h incubation period, H2O2
induced almost 60% cell death in medium treated groups (P<0.001), whereas 5µm-
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Fig. 5.2. BV-2 cell viability challenged by H2O2. Dose and time
dependent cell death were observed when BV-2 cells incubated with
different concentrations and periods of H2O2. Viable cells were shown
with various morphologies and white halos. Non-viable cells were ap-
peared as dark spheres after treated with Tyrpan Blue. (A) Time
dependent cell death of BV-2 cells incubated 1h with 0, 11, 55,
110µMH2O2. (B) Dose dependent cell death of BV-2 cells incubated
11µMH2O2 for 0-4h. (C) The quantitative data of time dependent cell
death. (D) The quantitative data of dose dependent cell death. All
data was normalized and compared with control groups. Data was
represented as mean±S.D. **P<0.05, ***P<0.01.
filtered Chi-DSNPs preserved approximately 20% extra viable cells on average (P<0.01).
A significant difference of these protective effects on the timing of the administration
of CHI-DSNPs between 0min and 15mins (P>0.05) was not detected. Additionally,
post-30min treatment of BV-2 cells with Chi-DSNPs did not provide a beneficial
effect (data not shown).
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Fig. 5.3. The inhibition of BV-2 cell proliferation induced by the
Incubation of H2O2 for 20hs. H2O2 induced the inhibition of cell pro-
liferation in all studied concentrations (***P<0.001). The inhibition
of cell proliferation was suggested to be dose-dependent. All H2O2
treated groups were normalized and compared with the control group
(0mM H2O2). Data was represented as mean±S.D.
5.3.5 The effect of Chi-DSNPs on cell proliferation challenged by H2O2
To investigate the effect of Chi-DSNPs on H2O2 induced inhibition of cell prolifer-
ation at 20 hours, mitochondrial enzyme activity was measured by the WST-1 assay.
Figure 5.5 shows that there stastically significant difference between the medium
and 5µm filtered Chi-DSNPs pre-treated healthy control groups was not detected
(P>0.05). This suggested that 0.2mg/ml NPs was well tolerated in BV-2 cell culture.
On the other hand, 0.05mM H2O2 induced an approximate 25% inhibition of cell pro-
liferation compared to healthy controls (5µm-np and medium; P<0.01). The admin-
istration of pre-4h incubation of Chi-DSNPs (1.2µm and 5µm-filtered) showed some
enhancement in cell proliferation subsequent to challenge by H2O2 (P>0.05). How-
ever, this enhancement was still significantly lower than healthy controls (P<0.05).
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Fig. 5.4. The neuroprotection by Chi-DSNPs on H2O2 challenged
BV-2 Cells. Data was normalized and compared with control (control-
PBS) groups. H2O2 significantly decreased the proliferation rate of
BV-2 cells compared with control groups (control-PBS). (∗∗∗P<0.001).
The administration of 5µm filtered group Chi-DSNPs, both at 0min
and post 15min, enhanced cell viability significantly compared with
H2O2-PBS treated group (
∧∧P<0.01). All data was represented
mean±SD.
It was observed that a statistical difference between H2O2-1.2µm Chi-DSNPs and
medium-5µm Chi-DSNPs was not reached (P>0.05).
5.3.6 Morphological analysis of BV-2 cells challenged by low and high
H2O2
The morphology of BV-2 cells was automatically recorded at 1h interval in a
temperature and humidity controlled culture chamber using a computer-managed
phase contrast microscope. The images of cells after H2O2 treatment at 0h, 2.5h
and 18h were selected to evaluate any changes in cell morphology. In healthy control
groups (Figure 5.6). A-C), cells appeared as adherent with elongated processes and
a normal rate of proliferation. In 0.05mM H2O2 group (D-J), the morphology of cells
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Fig. 5.5. The neuroprotection by Chi-DSNPs on H2O2 challenged
BV-2 Cells. Cell proliferation was inhibited significantly by long-
exposure of H2O2, compared with control groups (control-PBS). No
significant difference was detected between control groups (PBS and
NP treated groups) (P>0.05). A small increasing of cell proliferation
was observed between H2O2-1.2µm-np group, which compared with
H2O2 group, however the significant difference was not detected. No
significant difference was observed between 1.2µm-np group and the
control group (groups treated with NPs). Data was represented as
mean± SD. * P<0.05, **P<0.01, ***P<0.001. All data was repre-
sented mean±SD.
was distorted after 4h incubation . In(F), multiple dead cells formed clumps were
observed. In high magnification images(data not shown), the surface of cells became
very irregular and globular intrusions were observed. In 5.5mM hydrogen peroxide
group (G-I), cells started retracting their processes after 1h incubation. Some small
blebs were formed and swelling of cytoplasm was also observed (data not shown).
Eventually, these cells appeared to be dark indicating near or actual death. Multiple
small bright spots were detected in some single dead cell, suggesting there were holes
on these particular membranes (I). Nevertheless, the overall shape of the cells was
still approximately spherical.
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Fig. 5.6. The morphology changes of BV-2 cells induced by H2O2.
Phase contrast images of BV-2 cells incubated with different H2O2
concentrations (0, 0.05, and 5.5mM) at 0h, 2.5h and 18h. (A)-(C)
Medium control. (B-F) H2O2 0.05mM. (G-I) H2O2 5.5mM. Healthy
cells appeared as spheres with white halos (A-E, G). Dead cells ap-
peared as dark ones (H-I). (F) injured or non-viable cells formed clus-
ters.
5.3.7 Fluorescence imaging of BV-2 cell death induced by low and high
H2O2
The mode of BV-2 cell death was analyzed by dual-fluorescence staining, which
combined FITC-Annexin-V (staining of phosphatidylserine on the membrane) with
Propidium Iodine (PI) (intercalating with DNA base pairs). PI is membrane imper-
meant. Once the dye enters the cell membrane cytosol and binds with nucleic acids,
the fluorescent intensity is enhanced by 20-30 fold [169]. Since the loss of membrane
integrity is a pathological hallmark of necrotic cell death, only necrotic cells fluo-
rescence red due to PI staining. [170]. Necrotic cells were stained with both PI (in
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the nucleus) and FITC (on the membrane) whereas apoptotic cells were stained only
with FITC (on the membrane) [171]. In Figure 5.7 (A-C) only one cell was detected
to be stained with FITC-annexin-V/PI. Photomicrographs D-F show that BV-2 cells
treated with 5.5mM H2O2 were stained bright red PI on the nucleus and some FITC
on the membrane, which suggests necrosis as the major mechanism of cell death.
We did not detect any cells stained only with FITC-suggesting that these cells did
not undergo apoptotic cell death. Interestingly, the treatment of 0.1mM (G-I) and
0.05mM H2O2 (J-L) resulted in the reduction of annexin-V/PI stained cells, but also
led to cells stained only with FITC. The majority of these dead cells were stained
with FITC only, which indicated that long exposure to a low dose of H2O2 induced
mostly apoptotic cell death, combined with some necrosis.
5.3.8 SSEP
SSEP of all animals were recorded and monitored prior to the compression injury,
immediately post-injury, in Day 1, in Week 1 and in Week 2. The representative
records of SSEP at different time points in ChiNP treated groups were shown in Fig-
ure 5.8. After the compression injury, the SSEP conduction through the lesion was
blocked and a “flat signal” was recorded. However, the SSEP conduction through the
median nerve-cortex circuit was intact. The preserved SSEP in the control circuit
demonstrated the normal electrophysiological function above the lesion area. In all
16 ChiNP treated animals, 4 of these died prior to the final physiological measure-
ment. In the remaining ChiNP treated animals, a small signal was recorded in Week
1 and an increased signal was observed in week 2. Instead of complicating evalua-
tion by periodic scoring, we statistically compared only those animals that survived
until the end of the study. This difference between “controls”-no SSEP signals and
“experimentals”- the presence of SSEP signals was strikingly statistically significant
(P<0.001).
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Fig. 5.7. Fluorescence images of BV-2 cells challenged with H2O2.
Only one cell in the image was observed to be stained by PI and FITC
which indicated the high cell viability in the medium-control group
(A-C). Cells incubated with H2O2 (5.5mM-4h) resulted in mainly
necrotic cell death (stained by PI or PI and FITC, shown as red
or yellow dots). However, cells incubated with H2O2 (0.05mM-20h
and 0.1mM-20h) resulted in mainly apoptotic cell death (stained by
FITC only, shown as green dots). PI and FITC signal was repre-
sented as red and green color, respectively. Cells with yellow color
indicated the co-stain of PI/FITC dyes. (A-C) medium control-20h,
(D-F) 5.5mM-4h, (G-I) 0.1mM-20h, (J-L) 0.05mM-20h.
5.4 Discussion
5.4.1 The choice of microglia cells
Our previous study showed that chitosan nanoparticles exhibited neuroprotective
effects in a acrolein-challenged PC12 cell model [27]. PC12 cells are widely used
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as a model system for neuronal studies. In this work, we extend the investigation of
potential protective effects of chitosan nanoparticles on neuroglia cells. The neuropro-
tection of glial cells has significant therapeutic impact as well as practical advantages:
1). Neuroglia cells are supporting cells which are critical for the survival and func-
tion of neurons [164, 172, 173]. The co-culture of glia and neurons indicate that glial
cells can protect neurons by directly releasing glutathione into the extracellular en-
vironment - helping to maintain antioxidant levels sufficient to protect against ROS
mediated damage. Neurons cultured in glial conditioned medium were also capable
of up-regulating the r-glutamylcysteine synthetase (rGCS) gene whose activity is a
rate-limiting step in de novo glutathione synthesis. 2). Moreover Glia cells have been
shown to be more resistant than neurons to oxidative stress induced by H2O2 [148].
CNS neuroglia cells include macroglia (astrocytes, oligodendrocytes, radial glia,
and ependymal cells) and microglia cells [174,175]. In SCI, the activation of astrocytes
can result in a pathological gliosis suggested to create a harsh environment for axon
regeneration. Oligodendrocytes form the myelin sheaths around axons and are vul-
nerable to oxidative attack. Microglia are resident tissue macrophages of CNS. They
act as the initial innate immune response following CNS injuries. In SCI, the role
of microglia can be protective and/or destructive [173,176–178]. Activated microglia
can give rise to microglia/ macrophages which release pro-inflammatory cytokines and
proteases after SCI and it is considered as the destructive effect. On the other hand,
microglia can be polarized into M2 macrophages to promote neural repair during the
intermediate stages of SCI.
In this work, we used BV-2 cell line, an immortalized rat microglial cell line, which
shares properties with activated microglial cells, such as antigen profile (LPS triggered
TNF-alpha release) and a phagocytic capacity [179, 180]. The major advantages of
using cell lines other than primary cells are: 1) immortal cells are convenient for
culture and passage. 2) as an immortal cell line, they lead to significantly reproducible
results whereas using primary cells might generate variable results due to the impurity
of the cells. The downside of using cell line is that the response activated in a cell line
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might not be as close as if it is generated from the primary cells, particularly if the
research focus is a particular molecular/biochemcial pathway. Instead, the underlying
mechanism of H2O2 induced apoptotic cell death is shared across many different
cell types, including endothelial cells (EC), melanoma, macroglia, and microglia cell
lines [153,161,166], which is characterized by a initiation of apoptotic cascade signals,
such as caspase-3 and the activation of mitogen-activated protein kinases (MAPKs).
Therefore, using BV-2 cell lines was validate to investigate the neuroprotection by
ChiNPs on a H2O2 induced cell death model.
5.4.2 Understanding the role of H2O2 in SCI
H2O2 is widely used as an oxidative stress molecule in many injury and neurode-
generative models. Liu DX et al (1999) reported a significant elevation of intracellular
level of H2O2 30 mins after a weight drop induced SCI and lasted over 11h in this rat
SCI model [181]. In his work, H2O2 was suggested to be derived from O
·−
2 . The post-
activation and long lasting increase of H2O2 indicated that it was not an immediate
response to SCI, which consequently, confirmed the role of H2O2 in secondary injury
of SCI.
Here, we established an H2O2 induced ROS cell death model using different H2O2
concentrations and incubation periods. The purpose of constructing different profiles
of H2O2 induced cell damage was to find the concentration range that can mimic
the ROS-induced cell damage seen after SCI, and secondly to investigate the neu-
roprotective ranges for Chi-DSNPs. ROS-SCI induced cell death is a combination
of necrosis and apoptosis [10, 182–184], depending on concentrations and incubation
times of H2O2. Our new results show that short exposure (1-4h) of high doses H2O2
(11-110µM) induced a time or/and dose dependent necrotic cell death (Figure 5.2);
whereas long exposure (20h) of low doses H2O2 (0.05-0.1µM) results in mostly apop-
totic cell death (Figure 5.7) as well as a significant suppression of cell proliferation
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(Figure 5.3) [185]. The selection of H2O2 concentration was based on our preliminary
data (data not shown) and previous work [153,161,166].
We observed that more than 80% necrotic cell death at 4h after incubation with
11mM H2O2. The elevation of hydroxyl radicals was also observed in the same period
in a weight drop-induced SCI animal model [183, 186]. It was also found that the
administration of H2O2 induced the reduction of labile iron pools, indicating enhanced
conversion of H2O2 into hydroxyl radicals catalyzed by iron. However, Liu only
monitored induced cell death after 20h of SCI and more immediate evaluations were
not conducted. Considering the elevation timing of hydroxyl radicals in Liu’s work
and H2O2 induced cell death (revealed here), a concentration of 11 mM is likely too
high to produce a pathologically relevant cell death in an experimentally induced SCI
study. Therefore, we reduced the concentration of H2O2 to a more realistic 5.5 mM
to gauge the protective effects by Chi-DSNPs.
5.4.3 Understanding the Chi-NP results
Our results show that 5.5mM Chi-NP protected microglia cells from hydrogen
peroxide (2.5h) (Figure 5.4). The neuroprotective effects of Chi-NP can be deduced
from lipid interactions with the chitosan polymer. Chitosan can significantly “seal”
the membrane breaches/holes produced by mechanical forces [26,27]. H2O2 can induce
LPO, resulting in increased membrane permeability. Considering the presence of
H2O2 in the bathing medium, cellular membranes are the first cell component to be
damaged. Our results also suggest that the larger sized (5µm-filtered) Chi-DSNPs
had a stronger protective effect than the smaller size (0.45µm-filtered) of NPs. One
possible reason might be associated with the availability of the number of chitosan
polymers and the hydrophilic radius of the NPs themselves. Compared with small
Chi-NP, the larger ones incorporate a higher amount of chitosan polymers - which in
turn can react in a more robust fashion and occupy a larger surface area with multiple
membrane lipids.
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We also studied the results of a 20h incubation of 0.05mM hydrogen peroxide on
BV-2 cells. No significant improvement of cell proliferation was observed between
control and Chi-NP treated groups. At first glance, our “rescue” experiments had
unexpected results. In order to investigate the reason, we conducted a morphologi-
cal analysis in bright field and a cell death study with annexin-V/PI stainings. The
morphological analysis of BV-2 cells induced in two H2O2 conditions showed very dif-
ferent results (Figure 5.6). Cells in the high concentration of H2O2 (5.5mM) retracted
their processes but the overall morphology was still preserved. However, cells in the
low concentration of H2O2 (0.05mM) formed clusters where irregular and globular
intrusions were observed. Results (Figure 5.7) from fluorescence staining confirmed
increasing occurrence of apoptotic cell death (FITC staining) in 0.05mM H2O2. Both
fluorescence staining and bright field imaging suggested that the outcomes observed
in “rescue” experiments can be explained by cells dying from either apoptosis or
necrosis. Actually, necrosis, apoptosis or a combination of the two is commonly ob-
served in H2O2 induced cell death [10,159,182–184]. Therefore, our data supports the
notion that H2O2 at low dosage but at long incubation time likely leads to apoptosis.
High dosages of toxin, but with very short incubation times are more associated with
necrosis. Neuroprotection by Chi-NP in “rescuing” cells from necrosis is might be
due to the a physical interactions of chitosan polymer with compromised membrane
lipids [26,27]. This was observed in 5.5mM H2O2 treatments. In 0.05mM, even though
the low concentration of H2O2 was not immediately as “toxic” as at higher concen-
trations in the acute phase (0-4h), this level triggered apoptotic cell death which is
not reversible.
Other studies also suggest the anti-oxidant effects of a pre-incubation with chi-
tosan, but with different periods, ranging from 30mins to 24h. We do not wish to
follow this line of investigation as it is impracticable outside of the laboratory and
may not reveal any useful insights into mechanisms of action and/or integration of
the polymer in injury or disease. The beneficial effects of chitosan also depended on
the MW of chitosan, cell types tested, and the nature of “challenge” toxins [153,166].
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The uptake of chitosan / Chi-NP by A549 cells was observed in a dose and time-
dependent way [187]. We emphasize however that anti-oxidant therapy has never
been useful outside of animal laboratory models of CNS injury [10]. While in the
acute necrotic cell death, a hypothesized anti-oxidant effect might not be sufficient
to neutralize H2O2 and dampen so-called ROS mediated damage. However, it is just
as likely that direct treatments with potent antioxidants may not prove beneficial
either. The accepted mechanism for an inhibition of necrosis is via the sealing effect
of poloxamers, poloxamines, PEG, and Chitosan followed by spontaneous membrane
assembly in regions of defect [1, 10, 22, 26]. It was also suggest that the incidence of
apoptotic cell death in chronic CNS injuries is grossly exaggerated [10].
5.4.4 Comparisons of SSEP recovery after compression injury with dif-
ferent treatments (Chi-NPs, Saline and Silica NPs)
In this work, the presence or absence of SSEP through the lesion was used as
the criteria to study the performance of therapeutic effect of ChiNPs. Our results
showed that no recovery was observed in the silica NPs treated groups and the saline
treated groups (in our previous studies [25]. On the other hand, the conduction in
ChiNP treated groups was shown to start some level of recovery in 2 weeks of the
administrations of NPs.
Since SSEP mainly monitors the sensory function at the dorsal column of the
spinal cord, other functional tests might be also conducted in the future to provide
the effect of ChiNPs in the perspective of motor function. The cutaneous trunci
muscle reflex (CTM) was used as a tool to evaluate behavioral recovery in rats and
guinea pigs [144]. CTM reflex is a reflexive contraction of the skin of the back,
stimulated by a light physical touch of the skin. Different from SSEP, CTM reflex
involves both sensory and motor circuitries. Details of the anatomical basis of CTM
reflex can be found in Borgens 2003 [1]. Successful applications of CTM reflex was
observed in SCI guinea pig studies [21,22].
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5.4.5 The in vivo biodistribution and nanotoxicity of ChiNPs
As the advantages of nanomedicine compared with the delivery of bulk materials
have been increasingly recognized in recent years, the investigations of biodistribution
and nanotoxicity of nanomedicine also increases [56,188–191]. The biodistribution of
ChiNPs has been studied in many routes of administrations and organs: intravenous,
ocular, oral, pulmonary and liver [192]. Even though these NPs are all based on
chitosan polymer, the variety of size and surface properties allow them to have various
activities in vivo [193]. The accumulation of NPs in the body was influenced by
many effects: (1) the retention effect due to the leaky vascular structure and the poor
lymphatic drainage system in tumors [168]; (2) the mucoadhesion effect due to the
interaction between chitosan and the mucus layer of the ocular mucosa [194,195]; (3)
the elimination effect due to the clearance by the reticuloendothelial organs (liver) and
the filtration organ (kidney) [167]. The toxicity of ChiNPs were also studied in bare
NPs [128,143], in gene delivery (siRNA and DNA) [196,197], and drug delivery [198].
Overall, the application of ChiNPs in cell and animal studies is suggested to be safe
[192]. Our future work is to investigate the biodistribution of ChiNPs in SCI animal
models and elucidate the actions of ChiNPs after the intravenous administration.
5.5 Conclusion
In conclusion, Chi-NPs partially spared cells from necrotic cell death which was in-
duced by acute H2O2 incubation. The mechanism of the neuroprotection by Chi-NPs
might be associated with the interaction between chitosan polymer and membrane
lipids which in turn facilitated the membrane restoration. Our in vivo study showed
that the immediate subcutaneous administration of Chi-NPs results in some level
of the conduction of SSEP 1 week after the compression spinal injury performed in
guinea pigs.
108
Fig. 5.8. Somatosensory evoked potential recordings in control and
injured guinea pig spinal animals. The top panel (sample SSEP) con-
sists of a single and three overlapped measurements of SSEP. The
single waveform is a representative record of SSEP collected in a
normal animal, which was an average of 3 overlapped traces (each,
the average of 120 consecutive measurements, shown at below) The
lower panel (Control and Chitosan-treated) presented averaged sig-
nals: SSEPs from a control animal (on the left) and from a Chi-NPs
treated animal (on the right). A. The eliminations of SSEPs were
observed through the lesion in both animals (control and Chi-NP
treated) after the compression injury on the cord. B. The readings of
intact SSEP were obtained from median nerve stimulation/recording
in both animals throughout the observation period. Note the appear-
ance of weak SSEP recorded in only the ChiNPs treated animal in
week 1 (C, on the right) and week 2 (D, on the right). However,
SSEP in the Control animal was shown as a “flat” line throughout
the observation period (C, D, both on the left) which indicated the
absence of the signal conduction through the lesion. The time base is




In this thesis, we presented data of the affinity of TMR-PSiNPs at the injured sites
of spinal cord tissues. We fabricated ChiNPs based on an ionic gelation method and
investigated the neuroprotective effects by chitosan and ChiNPs in SCI associated
cell, tissue and animal models. The experimental findings and interpretations were
summarized below:
1. Using an ex vivo compression model, PSiNPs were shown to accumulate sig-
nificantly at the damage sites of the spinal cord tissues (P<0.05). The fluorescent
intensity of TMR-PSiNPs was shown to be inversely proportional to the distance
from the site of the compression injury. The fluorescent intensity of TMR-PSiNPs
decreased significantly in intact regions, compared with the compression site. SEM
results were consistent with the result from fluorescence images. SEM results sug-
gested that larger amount of PSiNPs was located at the damage site compared with
the intact sites.
2. Using ex vivo compression and transection models, chitosan polymer was sug-
gested to facilitate the restoration of membrane integrity by suppressing the random
exchange of molecules across the membrane breaches. The incubation of compressed
spinal cord segments with chitosan inhibited significantly the leakage of LDH com-
pared with PBS treated control ones (P<0.05). In addition, the incubation of tran-
sected spinal cord segments with chitosan excluded the internalization of TMR probes
(P<0.05), compared with PBS treated ones.
3. A significant difference of the effects of the neuroprotection based on DAs
and MWs of chitosan was not observed (P>0.05). The preference of FITC-chitosan
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(DA0%) on the damage sites of the spinal cord segments was not observed as well
(P>0.05).
4. Two types of ChiNPs were successfully constructed: ChiDSNPs and ChiTPP-
NPs, based on an ionic gelation method. ChiNPs appeared as spheres.
5. The bimodal size distribution was observed in both types of NPs (Chi-TPPNPs:
20-40nm and 100-200nm; Chi-DSNPs: 40-60nm and 200-300nm).
6. The sizes and zeta potentials of NPs were associated with the volume ratio of
chitosan / DS and chitosan / TPP. As the volume of TPP or DS increases, the size of
NPs decreases, whereas stronger binding forces between oppositely charged polymers
were suggested. Particularly, the zeta-potential of MC-DSNPs in de-ionized water
was reversed from positive to negative, as Chi/DS ratios decreased from 5:3 to 5:8.
7. A significant impact of pH on the formation of ChiTPPNPs was not observed.
ChiTPPNPs were formed successfully at both pHs of TPP (4.3 and 9.1). ChiDSNPs
were only formed at pH of DS (4.6). However, no NP but polymer aggregations were
synthesized at high pH of DS (pH>6).
8. ChiNPs were stable when incubated in the buffer with low ionic strength
(less than 0.1 XPBS). The incubation of MC-TPPNPs in the buffer with high ionic
strength (more than 0.5 XPBS) induced a size increase (5 times) and a decrease
of zeta-potential (80%) (P<0.05), These changes indicated the aggregation of MC-
TPPNPs in the high ionic strength environment. The zeta-potential of MC-DSNPs
was decreased significantly as well in the high ionic strength (P<0.05). However, a
significant change of size was not observed in MC-DSNPs.
9. Using H2O2 challenged BV-2 cell models, the neuroprotection by Chi-NPs was
suggested to rescue cells undergoing necrotic cell death.
10. Cell death and the inhibition of cell proliferation induced by H2O2 were
concentration and time depedent. BV-2 cells incubating with a lower (0.05mM)
concentration of H2O2 for a long period of time (22h) produced mainly apoptotic
cell death. BV-2 cells incubating with a higher (5.5mM) concentration of H2O2 for a
short period of time (2-4h) resulted in mainly necrotic cell death.
111
11. Using an in vivo compression injury model, the subcutaneous administration
of Chi-NPs restored partially the conduction of SSEP after 1 week of NPs’ injection,
while the control groups treated with silica NPs or saline still showed no recovery
of function. The conduction of SSEP was blocked completely after the compression
injury performed.
Our studies have showed that the application of chitosan successfully blocked
the exchange of molecules through the membrane breaches which were produced
by mechanical forces. The application of Chi-NPs dampened the cytotoxicity of
hydrogen peroxide, rescued BV-2 cells from necrotic death and restored the sensory
signal conduction through the lesion. In addition, the affinity of PSiNPs at the
injured spinal tissues indicated that PEG can be used to target damaged cells. Our
studies did not find a DA and MW dependent neuroprotective effect by chitosan. We
also learned that the properties of Chi-NPs were significantly affected by high ionic
strength.
6.2 Future Work
SSEP is a sensory functional test which evaluates the sensory signal conduction
through the spinal cord. Other functional tests, such as the motor functional test,
cutaneous trunci muscle (CTM) reflex, need to be included to complete the under-
standing of the neuroprotective effects of ChiNPs in whole animal studies. Studies
of the biodistribution and the metabolism of Chi-NPs will also allow us to get more
information of the effect of Chi-NPs in the human body. Considering the affinity
of PEG at the membrane damage and the biodegradability and the neuroprotective
effects by chitosan and Chi-NPs, PEG-chitosan complex can be fabricated to com-
bine both targeting and neuroprotective effects. The beneficial effect of PEG-chitosan
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